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Abstract 
Objective To investigate maternal serum screening (MSS) in Newfoundland and 
Labrador. 
Design Cross-sectional anonymous physician and post-partum women surveys 
conducted between September and December 2003. Aggregate laboratory data for 
2003 were also assessed. 
Population Physicians practicing antenatal care in Newfoundland and Labrador 
in the previous 12 months (n = 490). Women (n = 300) who had recently given 
birth. 
Results The response rates for the physician and patient surveys were 60.4% 
(n = 293) and 66.7% (n = 200) respectively. Most physicians (88.8%) reported 
that they offer maternal serum screening to their patients. These physicians were 
divided among those who offered MSS to all women (63.5%) and those who 
offered MSS to selective groups of women (36.5%). Physicians who were 
younger, female and educated in Canada were more likely to offer MSS than 
physicians who were older, male and educated outside of Canada. Obstetricians 
were more likely to offer MSS and to offer the screening test to all women than 
family physicians. The majority of both physician groups reported that they would 
prefer a first trimester screening test. 
The majority (62.9%) of patients surveyed reported discussing MSS with 
their physician. Less than half ( 46.2%) of these women chose to undergo the 
prenatal screen. Women who underwent MSS were significantly older than 
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women who did not undergo the screening test. Twenty seven percent of patients 
surveyed underwent MSS. 
Data obtained from the Provincial MSS Program indicated that 22% of 
women undergo MSS. The overall false positive rate 1 associated with MSS in 
Newfoundland and Labrador was 13.1%. 
Conclusion MSS is not being used as a population based screening test. It is 
being offered to and used by selected groups of women. Further education and 
promotion of this prenatal screening test are necessary. 
1 A screening result that shows evidence of a disease or an abnormal condition although it (the 
condition being tested for) is not present. 
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Chapter 1 - Introduction 
1.1 Problem 
The Provincial Medical Genetics Program of Newfoundland and Labrador 
introduced the Maternal Serum Screening (MSS) Program in the beginning of 
2002. The goal of this program is to provide a risk estimate for Down's syndrome, 
Trisomy 18 and open neural tube defects for every pregnancy in Newfoundland 
and Labrador. The Canadian Task Force on the Periodic Health Examination 
(Canadian Task Force on Periodic Health Examination, 1994) has suggested that 
there is fair evidence to offer MSS to all pregnant women. This position is further 
supported by the Society of Obstetricians and Gynecologists of Canada (SOGC, 
1999). MSS is therefore becoming the 'standard of prenatal care'. 
After education and promotion throughout the province in July and August 
of 2002, the MSS rate was 19% in 2002 (Jennifer Moore, Personal 
Communication, June 22, 2004). There is little evidence to explain the low 
screening rate. The use of MSS is much higher in other parts of Canada, ranging 
from 48% in Ontario (Summers, 2003) to 68% in Manitoba (Karen MacDonald, 
Personal Communications, April 29, 2004). 
1.2 Purpose and Objective 
The goal of this study was to examine patterns of MSS use in 
Newfoundland and Labrador through a physician survey, patient survey and 
secondary analysis of laboratory data. 
The objectives of the physician survey were: 
1. to describe the characteristics of physicians who offered and did not offer MSS. 
Specifically, the study examined sociodemographic, practice, and training 
characteristics. 
2. to assess physician knowledge ofMSS. 
3. to explore physician opinion of MSS and methods to improve the test. 
The objectives of the patient survey were: 
1. to describe the sociodemographic characteristics of women who have and have 
not been offered MSS as well as those who have undergone and not undergone 
MSS. 
2. to describe the information provided to women regarding MSS as reported by 
women. 
The objectives of the laboratory data analysis were: 
1. to estimate the proportion of pregnant women in Newfoundland and Labrador 
who undergo MSS. 
2. to describe the characteristics of the patients who have undergone MSS. 
3. to describe the number of positive and negative test results. 
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1.3 Rationale 
This topic is of particular interest to the people of Newfoundland and 
Labrador, as the province has the highest incidence of neural tube defects in 
Canada, affecting four per 1000 births (Crane et al., 2001). This statistic 
underscores the need to develop a better understanding of the low uptake of MSS 
in the province. By examining data from physicians, patients and the testing 
laboratory, this study provides a more complete picture of perceptions about MSS 
and actual MSS screening practices. The study also identifies facilitators and 
barriers to improving the use ofMSS in Newfoundland and Labrador. 
Finally, this study assesses the impact of MSS provincial implementation 
in September of 2001. With the introduction of the MSS Program, the Provincial 
Medical Genetics Program has conducted province wide educational and 
promotional sessions, including television, radio and newspaper spots. A public 
health nurse traveled across the province and held MSS education sessions in 
every hospital which performed deliveries. This study will describe current use, 
offering an assessment of the impact of the education and promotional activities 
that have taken place. 
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Chapter 2 -Review of Literature 
2.1 Maternal Serum Screening 
Maternal Serum Screening (MSS) is a prenatal genetic screening test 
completed in the second trimester and determines a woman's risk of carrying a 
fetus with Down's syndrome, Trisomy 18 or an open neural tube defect. With this 
blood test it is possible to assess the individual risk of fetal neural tube defects, 
Down's syndrome and Trisomy 18 for any pregnant woman, regardless of her age 
or medical history. Thus, invasive diagnostic tests (such as amniocentesis) can be 
offered more selectively to those screening positive and detection rates can be 
increased substantially (Wald et al., 1988). All definitive prenatal diagnostic 
techniques are invasive and are associated with risk of pregnancy loss and have 
significant financial cost. Therefore, it is appropriate to offer these invasive 
techniques only to patients at highest risk. 
2. 2 Down 's Syndrome 
Down's syndrome (DS) is a genetic abnormality consisting of three copies 
of chromosome 21. It is the most common form of (genetically) inherited 
developmental delay, occurring with an incidence of approximately 1 of 700 
births in the general population (Ross & Elias, 1997). Down's syndrome is 
associated with a variety of congenital malformations including facial 
characteristics such as upslanting eyelids, protruding tongue and a flattened nasal 
bridge. Approximately 40% of infants born with Down's syndrome will have 
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congenital heart defects and all will have varying degrees of developmental delay 
(Ross & Elias, 1997). Other chronic health problems encountered by these 
individuals include gastrointestinal and musculoskeletal abnormalities, and 
increased rates of childhood leukemia and early Alzheimer's disease. Since the 
1970s, the life expectancy and quality of life of persons with Down's syndrome 
have increased dramatically. The most current life expectancy for babies born 
with Down's syndrome is 58.6 years of age (Glasson et al., 2002). 
2. 3 Trisomy 18 
Trisomy 18 is also a result of an extra chromosome; in this disease, there 
are three copies of the number 18 chromosome. It has an incidence of 
approximately 1 of every 6000 live births (Jorde et al. , 2000). The abnormalities 
associated with Trisomy 18 are generally not compatible with more than a few 
months of life. Fifty percent of the affected infants do not survive beyond the first 
week of life and only about 10% are still alive at 12 months of age (Jorde et al., 
2000). 
A third copy of chromosome 18 causes numerous abnormalities. Most 
infants born with this disease are underweight and appear weak and fragile. 
Affected individuals have numerous problems with their internal organs. 
Problems often occur in the lungs, heart, diaphragm and blood vessels. The infant 
may also have malformed kidneys and abnormalities ofthe urogenital system. 
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2. 4 Open Neural Tube Defects 
Open neural tube defects are caused by an opening in the spinal cord or 
brain which is thought to arise from a combination of genetic and environmental 
factors. Normally the neural tube closes at about the fourth week of gestation. A 
defect in closure or a subsequent re-opening of the neural tube results in an open 
neural tube defect. Examples of open neural tube defects are spina bifida, 
anencephaly and encephalocele. This prenatal disorder is of particular importance 
to Newfoundland and Labrador as the latest statistics (Crane et al., 2001) show 
Newfoundland and Labrador has the highest rate of open neural tube defects in 
Canada, affecting approximately 4 in every 1000 live births (although the rate of 
neural tube defects has been decreasing throughout Canada since folic acid 
fortification was introduced). 
Generally, the higher the defect occurs on the spinal cord and/or the larger 
the defect, the greater the disability. This disease can range from anencephaly 
which results in still birth or neonatal death to individuals with a neural tube 
defect who can lead productive lives. Associated conditions include paraplegia, 
bladder and bowel incontinence and other physical disabilities as well as mental 
impairment which occurs in approximately a quarter of the cases. 
2. 5 Risk Calculation 
Risk is calculated in MSS by measuring three biochemical serum markers: 
alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol (in 
combination with maternal age for assessing down syndrome and trisomy 18 
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risk). An algorithm has been created in which a patient's risk is modified up or 
down depending on whether the results of each of the four factors are more 
typical of the unaffected population or more typical of the high risk population 
(women with a fetus with Down's syndrome, Trisomy 18 or open NTD). When a 
serum sample is sent to the lab, the three biochemical markers are measured and 
compared to the unaffected population median for the same day of gestation. 
Although exact reported population biochemical levels may differ among labs, all 
labs standardize their results by comparing them to the unaffected population 
median. Therefore, the 'average value' from any lab for each of the markers in the 
overall population will be 1.0 multiple of the median 1 (Carroll, 1997). For 
example, the median maternal serum alpha-fetoprotein level for a woman carrying 
a Down's syndrome fetus is approximately 0.8 multiples of the median of the 
normal pregnancy median (Ross and Elias, 1997). Median maternal serum alpha-
fetoprotein is therefore about 20% lower in women carrying fetuses with Down's 
syndrome. 
Each of the three multiples ofthe median values (for each biochemical 
marker) and maternal age are then fed into a computer program which calculates 
individual risk for each prenatal disease taking into account the impact of all four 
factors. 
Using alpha-fetoprotein, human chorionic gonadotropin and unconjugated 
estriol, along with maternal age, MSS has a sensitivity of about 70% for Down's 
1 Once the blood test results are determined, a risk factor is calculated based on the "normal" 
blood tests for the testing laboratory. The average of normals is called the population median. Test 
results are reported to doctors as Multiples ofthe Median (MoM). The average value is therefore 
called 1.0 MoM. 
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syndrome, 75% for Trisomy 18 and about 80% for open neural tube defects. The 
specificity rates ofMSS are 92% for Down's syndrome, 99.8% for Trisomy 18, 
and 98% for neural tube defects. (Haddow et al., 1992; MacDonald et al., 1991; 
Wald et al., 1988; Norgard-Pedersen et al., 1990; Cheng et al., 1993; Phillips et 
al., 1992). This means 70% of Down's syndrome cases screened will yield a 
positive MSS result and 30% of Down's syndrome cases will be missed. Also, 
with a 92% specificity rate, 92% of fetuses without Down's syndrome will be 
correctly identified as true negatives and 8% of people who have MSS done will 
have a false positive. 
A blood test is considered to be "screen positive" for trisomy 18 or 
Down's syndrome when the sample contains unusual amounts of the three 
biochemical markers. The blood test is considered to be "screen positive" for an 
open neural tube defect when there is an abnormal amount of AFP. The patient's 
specific risk for each genetic anomaly is given as a ratio on the physician 
laboratory report. Screen positive for Down's syndrome is defined as when the 
chance of a baby being born with the disease is equal to or greater than 11385. 
Trisomy 18 is determined to be screen positive when the chance ofthe baby being 
born with the disease is at least 1/25. Screen positive for an open NTD means that 
the result is equal to or greater than 2.2 multiples of the median. 
If a screen positive result is the outcome, a physician following the 
guidelines of the provincial program is expected to arrange a detailed ultrasound 
to verify the weeks of gestation, to rule out multiple gestation, fetal death, and to 
examine the fetus for anomalies. If a follow up consultation is to be arranged, the 
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physician may meet with the patient to discuss the consequences of the screening 
test or he or she may have the patient meet with a genetic counselor. The 
counselor is specially trained to discuss the meaning of the screening results and 
possible further diagnostic testing to confirm the genetic abnormality. 
Amniocentesis is used to confirm DS and Trisomy 18, whereas, ultrasound is used 
to confirm a positive MSS screening result for an open NTD. 
2. 6 Genetic Counseling 
Before a patient can consent to MSS they should receive pretest genetic 
counseling. Genetic counseling involves giving information regarding the 
available methods of prenatal diagnosis, risks and benefits of various techniques, 
timing of diagnostic procedures, conditions for testing, current management of 
relevant genetic disorders, and accuracy of prenatal test results, which would 
include implications of false negative and false positive test results (Society of 
Obstetricians and Gynecologists of Canada, 1999). 
Counseling can be done by the physician or a person specially trained in 
genetic counseling. In Newfoundland and Labrador, physicians usually counsel 
their patients about MSS before they offer the prenatal screen. After the screening 
test is ordered, a negative screen result is sent directly to the physician, whereas a 
positive result is sent to the nearest genetic counselor who informs the physician 
of the screen result. The physician may counsel the patient about the test results 
and the options for further testing or they may send the patient to the nearest 
genetic center to meet with a genetic counselor. Trained genetic counselors are 
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located in the regional genetics centres in St. John ' s, Gander and Comer Brook. 
2. 7 Potential Problems with MSS 
The three biochemical marker levels vary throughout a woman's 
pregnancy and can only be analyzed for maternal serum screening between 15 and 
20 gestational weeks. The MSS blood test therefore operates within a narrow time 
window of a woman's pregnancy and requires unprecedented coordination among 
physicians, laboratories, genetics counselors, and prenatal diagnostic centers. 
Several potentially serious problems can arise with the use of MSS. These may 
include inadequate provider knowledge which may result in sub-optimal 
counseling or a complete lack of counseling and/or screening consent. There are 
also complaints of raised levels of anxiety among women who experience the 
delay in definitive diagnosis associated with MSS (Madlon-Kay et al., 1992). 
Another potential problem surrounding MSS is lack of timely follow-up of 
positive tests; in certain locations and regions there are problems with access to 
screening ultrasound, amniocentesis, specialized genetic counseling services, and 
services for pregnancy termination (Carroll, 1997). The timing surrounding the 
screening test is an issue for some physicians and patients as the screen requires 
that important decisions such as amniocentesis and the potential of pregnancy 
termination are made relatively late in a woman ' s pregnancy. Decisions 
surrounding pregnancy termination are especially controversial in Newfoundland 
and Labrador. The province has a large religious population which often have 
difficulty with the idea of pregnancy termination. 
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2. 8 MSS in Newfoundland and Labrador 
The most recent and relevant physician survey regarding MSS was done 
by Chandra et al. in 2000 (Chandra et al., 2003). In this study Newfoundland and 
Labrador physicians involved in prenatal care were contacted through a postal 
questionnaire. This survey was completed before the introduction of the 
Provincial Maternal Serum Screening Program and aimed to assess physician 
practice and knowledge of MSS. Chandra et al. found that 29% of respondents 
offered the screen to all pregnant women. A further 34% of respondents discussed 
it only with patients over 35 years of age at delivery. Of the physicians that 
ordered MSS, 30% did so outside ofthe correct screening time frame of 15 to 20 
gestational weeks. 
The study done by Chandra et al. (2003) discovered that physicians were 
not adequately informed about MSS. She found that physicians demonstrated a 
lack of overall knowledge of MSS. They were unaware of the appropriate 
gestational age at which MSS should be offered and the screening rates (e.g. false 
positives, true positives, etc.) associated with MSS. This is a cause for concern 
because if women are to provide consent for MSS, they should understand the 
purpose of the test, the likelihood of false positives and negatives, and the 
implications of the possible results. Moreover, it has also been suggested that it 
has been the lack of physician counseling time discussing MSS that has 
contributed to patients forgoing the screening test (Personal Communication, 
Claire Blight, Nova Scotia Department of Health, February, 2003). 
I l 
In their 2000 study, Chandra et al. discovered that a number of physicians 
were offering MSS only to women over 35 years of age or to women with a 
family history of Down's syndrome or NTD. This is a cause of concern as this 
screening test uses population-based risk ratios and it is therefore inappropriate to 
recommend MSS solely to women in these higher risk groups. 
2. 9 Physician Opinion ofMSS 
Prenatal screening and MSS are complex and value-laden processes. 
Physician opinion of MSS has been studied in other parts of Canada (Carroll et 
al., 1997) and throughout the world (Hemminki et al., 2000; Green, 1994; 
Hemminki et al., 1999). 
A study done in Ontario discovered that the majority of physicians 
surveyed recommended that their provincial MSS program should be changed or 
scrapped (Carroll et al., 1997). Reasons cited by physicians included "Too many 
normal pregnancies have positive MSS results," and "MSS causes too much 
anxiety for women". There were also studies done in Finland that surveyed health 
care providers regarding MSS. These studies found that there was support for 
such screening, but many physicians acknowledged the ethical and psychological 
implications of such testing (Hemminki et al., 1999; Hemminki et al., 2000). 
Another physician opinion study out of England found that physicians felt they 
did not have adequate training or resources to counsel all the women to whom 
screening was offered. The investigators suggested that the lack of available 
counseling was consistent with the high prevalence of problems associated with 
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women not understanding the test (Green, 1994). These surveys gave physicians 
an opportunity to suggest possible changes that could improve their MSS 
programs. For example, the physicians in England and Wales suggested that there 
was an urgent need to determine of what counseling should consist and who 
should undertake it. Newfoundland and Labrador physicians require the same 
opportunity to comment on improvements if the MSS program is to better suit the 
needs of the physicians and their patients. 
An opinion often cited by physicians is that prenatal screening is offered 
too late in pregnancy (Madlon-Kay et al., 1992). Prenatal screening tests are 
constantly evolving and first trimester prenatal screening is now being offered in 
other Canadian provinces, most recently in Halifax, Nova Scotia (Personal 
Communications, Claire Blight, November, 2002). 
2.10 Patient Acceptance o[MSS 
Physician acceptance and use of MSS have been well documented, but 
acceptance of MSS by patients has been less studied. Chandra et al. (2003) asked 
physicians if they were offering MSS to their patients but did not ask if patients 
generally accepted the screening test. Physicians may have concerns about the test 
and its limitations, which may be conveyed to their patients who then opt not to 
undergo the screening test. A 1992 survey of American physicians found that 
87% of the physicians offered maternal serum alpha-fetoprotein testing. However, 
the physicians noted that relatively few patients chose to have the test done 
(Madlon-Kay, 1992). Therefore, asking patients about MSS may help us 
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determine whether it is patient or physician acceptance which is influencing the 
MSS rate in Newfoundland and Labrador. 
2.11 Physician Factors Affecting Uptake 
Factors that have been associated with early uptake of Maternal Serum 
Screening have been associated with the sex of the physician (Woodward et al. , 
1997). Woodward et al. (1997) completed a survey of physicians a year and a half 
after the Ontario Ministry of Health introduced a MSS program to be offered to 
all pregnant women as a province wide pilot. Woodward discovered that more 
female physicians offered MSS to all their patients and were more knowledgeable 
about MSS than male physicians. The number of deliveries performed per year by 
the physician has also been shown to influence MSS adoption. It has been found 
that the more deliveries a physician performs, the more likely they were to offer 
MSS (Yankowitz et al. , 1996; Carroll et al. , 1997). Also, the specialty ofthe 
physician has been shown to be a predictor of early MSS use. Obstetricians have 
been found more likely than family physicians to offer MSS (Sadler, 1997; 
Chandra et al., 2003). 
Physician use of MSS has also been found to vary according to regional 
area. A study done in Ontario by Permaul-Woods et al. (1999) found that 
physicians in the northwest and rural regions of Ontario were less likely to 
routinely offer MSS to all women compared to physicians in urban centers. In 
Manitoba, physicians outside of Winnipeg were found to be less likely to do a 
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Down's syndrome prenatal screen 2 than physicians in the city (Chodirker & 
Evans, 1993). However, Chandra et al. (2003) found no such urban/rural 
difference in Newfoundland and Labrador. 
2 Maternal serum alpha-fetoprotein screening as a single biochemical marker was offered for 
Down's syndrome screening before the triple biochemical marker screening test became available. 
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Chapter 3 - Methods 
This is a cross sectional study which used three data sources: a physician survey, 
a patient survey and aggregate laboratory data. 
3.1 Physician Survey 
The physician survey consisted of a postal survey of all obstetricians and family 
physicians 1 practicing in the province ofNewfoundland and Labrador. Physicians who 
provided antenatal care during the preceding twelve months were included in the study. 
3.1.1 Data Collection 
The list of eligible physicians was created from the mailing list of currently 
licensed physicians from the Newfoundland Medical Board on August 15th, 2003. The 
list included 490 family physicians and 35 obstetricians practicing in the province, for a 
total physician study population of 525. The survey package sent to physicians included a 
questionnaire with return envelope and a postcard. The postcard and return envelope both 
had business reply postage stamps attached. Physicians were requested to separately mail 
back the completed survey and the reply postcard to permit anonymity of responses. The 
postcard displayed the corresponding physician's name and address. Its purpose was to 
distinguish physicians who had completed and returned the questionnaire so that 
subsequent mail-outs were sent only to non-respondents. To ensure anonymity neither the 
questionnaire nor its return envelope had the physician name or any traceable information 
attached. 
1 General practitioners and those who had family medicine specialty were grouped together as family physicians. 
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The physician survey consisted of four mail-outs between the period of 
September 23rd, 2003 and November 13th' 2003. To promote a higher response rate, the 
initial survey was followed up with three reminder surveys. The third followup was hand 
delivered to the offices of physicians on the A val on peninsula, while physicians in the 
rest of the province were contacted by telephone. 
3.1.2 Survey Instrument 
The physician questionnaire was adapted from the questionnaire used by Carroll 
et al. (1997) to assess the Ontario Maternal Serum Screening program. The validity of 
this survey instrument had been achieved through focus groups and pilot testing which 
have been discussed elsewhere (Carroll et al., 1997). The questionnaire was shortened 
and some of the questions were altered to better represent the MSS Program in 
Newfoundland and Labrador. Questions regarding physician income, work hours and 
open-ended questions regarding patient and physician MSS brochures were omitted. 
Chandra et al. (2003) also used a version of the survey developed by Carroll et al. (1997). 
The questionnaire used in my study differed from that of Chandra et al. in that it was 
longer and it used more open-ended questions. Instead of asking whether the physicians' 
MSS practice had changed in the past 18 months, I asked how their MSS practices had 
changed in the past 18 months: whether they were offering MSS more often; less often; 
or the same amount. With regards to MSS information they have come across, Chandra et 
al. asked if they had read any material regarding MSS. I chose to ask exactly where they 
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had been exposed to MSS information (the internet, medical journals, newspapers, 
colleagues, etc.). 
The first section of the survey contained questions regarding the physicians' 
personal and professional practice characteristics. These characteristics included age, 
gender, specialty, years in practice and the size of the community in which the physician 
practiced. The questionnaire also asked whether the physician provided antenatal care 
and included several questions regarding the physicians' antenatal practice. Questions 
included how many years the physician had been providing antenatal care, to what 
gestational week care was provided and the number of pregnant women cared for in the 
past twelve months. The questionnaire is presented in Appendix A. 
The second section of the survey explored physician opinion and knowledge of 
MSS. Physicians were asked if they offered MSS, and if not, why. Physicians who 
offered MSS were asked to which groups of women they routinely offered the screening 
test, and to provide some MSS practice information. Practice information included the 
amount of time typically spent discussing MSS with a patient, the percentage of patients 
who chose to undergo the screening test as well as the turnaround time for notifying 
patients of positive and negative MSS results . 
Questions posed to determine physician knowledge of MSS included the correct 
time frame to offer MSS; the false positive and the true positive rates for each genetic 
disease screened; whether the physician was aware of the Provincial MSS Program and a 
question regarding the sources of information pertaining to MSS knowledge. The 
questionnaire also asked whether the physician believed MSS could mislead patients to 
believe that physicians could guarantee a healthy baby and whether a first trimester 
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screening test was preferable. The questionnaire finished with an open-ended question 
regarding their opinion of the MSS program and whether they had any comments on 
MSS in Newfoundland and Labrador. 
To ensure the clarity of the questionnaire, the questions were pre-tested with 
medical students, graduate students, faculty, genetic counselors and physicians. The 
questionnaire was deliberately kept brief to encourage a high response rate and utilized 
both open-ended and closed questions. 
3.1.3 Data Management 
The survey data were entered and analysed using SPSS software version 11.5 
(Statistical Package for the Social Sciences). The data were cleaned by running 
frequencies and cross tabulations to identify data-entry errors and impossible responses. 
Errors were corrected by comparing the survey database with the original document. 
Physicians who did not provide antenatal care were excluded from the analysis. 
3.1. 4 Data Analysis 
The location of practice variable was initially recorded in five categories which 
were subsequently reduced to three: urban (>20,000), semi urban (1 0,000- 19,999), town 
(5,000- 9,999), small town (1,000- 4,999) and rural (<999). In the final categorization 
the new rural category included the town, small town and rural responses. 
Physician knowledge was determined by the physician identifying the correct 
gestational age to order MSS and the false positive and the true positive rates for each 
genetic disease screened. False positive and true positive rates were determined to be 
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correct ifthe physician's response was within 5% of the recorded literature value for each 
measure. 
Frequencies were used to describe the characteristics of the sample as a whole. 
Chi square tests, t tests, ANOV A and, if applicable, Boneferroni tests were used to 
identify differences between specialty (family physicians versus obstetricians), gender, 
and MSS practice (whether MSS was offered to all patients, some patients or no patients, 
i.e. not offered). Frequencies were used to analyze responses from categorized open-
ended responses including reasons for not offering MSS. Lastly, physician comments and 
opinion of the MSS program were analyzed, comparing the differences between the 
different MSS user types. 
3.2 Patient Survey 
The patient survey consisted of a self-administered written questionnaire 
completed by women within forty-eight hours of giving birth at the Women's Health 
Centre of the Health Care Corporation of St. John's in Newfoundland. The site was 
chosen due to the volume of patients seen, ensuring cost-efficient data collection. This 
setting is also the only tertiary care obstetric hospital in the province. The Women's 
Health Centre is not exclusive to pregnancies of high risk, but is visited by women living 
in St. John's and surrounding areas. 
3. 2.1 Sample 
The sample frame consisted of a convenience sample of 300 women. Given that 
the Women's Health Centre has approximately 2100 births per year, this sample size 
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represents approximately 15% of the total population. Those who gave birth to a single 
baby (as MSS can only be used for single births) and who understood sufficient English 
to complete the questionnaire were eligible for the study. 
3. 2. 2 Data Collection 
The surveys were distributed and collected by Medical Service Aides (MSAs)2 
between October 8th and November 27th, 2003. Every two weeks I dropped off surveys 
to the MSAs, and collected completed questionnaires at this time. The MSA identified 
potential participants as women who gave birth within the last forty-eight hours on the 
maternity ward. The MSA visited the women in the morning to drop off the surveys and 
then returned later that day to collect the completed surveys. Women were asked not to 
sign the questionnaire or report any identifying personal information. Questionnaires 
were coded with a study number. 
3. 2. 3 Survey Instrument 
The survey asked applicable questions which were extracted from the physician 
MSS survey. Questions covered the patients' exposure to MSS, time spent discussing 
MSS with their physician and whether they chose to undergo the prenatal genetic 
screening test. Questions regarding patient age and the size of the community in which 
they lived were also asked. 
This questionnaire was pre-tested on medical students, graduate students, faculty, 
genetic counselors and physicians to ensure clarity for participants. The questionnaire 
2 Medical Service Aides (MSAs) are support staff located throughout the hospital. 
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was kept deliberately brief as to minimize disruption to the new mothers. The patient 
survey presented in Appendix B. 
3. 2. 4 Data Management 
The survey data were entered and analysed using SPSS version 11.5 software 
(Statistical Package for the Social Sciences). The data were cleaned by running 
frequencies and cross tabulations to identify data-entry errors and impossible responses. 
Errors were corrected by comparing the survey database with the original document. 
3.2.5 Data Analysis 
The location of practice variable was initially recorded in five categories which 
were subsequently reduced to three: urban (>20,000), semi urban (1 0,000- 19,999), town 
(5,000- 9,999), small town (1 ,000- 4,999) and rural (<999). In the final categorization 
the new rural category included the town, small town and rural responses. 
Frequencies were used to describe the characteristics of the sample as a whole. 
Chi square tests, t tests, ANOV A and if applicable Boneferroni tests were used to identify 
differences (whether or not they had MSS) by age and place of residence. These groups 
of women were then analyzed for differences in sources ofMSS information and the 
amount to time physicians typically spent discussing MSS . 
3. 3 Laboratory Information 
Laboratory data were obtained from the Newfoundland and Labrador MSS 
Program with the permission of the Provincial Medical Genetics Clinic on March 5th, 
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2003. The data include the Provincial MSS uptake rate3, geographic utilization rates of 
the screening test and screen positive 4 and screen negative rates5 for the province for 
2003. Also included was information regarding the age of women who were using MSS 
in 2003. 
3. 3.1 Data Analysis 
Information was analyzed in aggregate form only. 
3. 4 Ethical Considerations 
The study required the participation of physicians, and women delivering between 
October glh and November 2i\ 2003. The Human Investigation Committee at the 
Faculty of Medicine, Memorial University of Newfoundland (Appendix C) and the 
Research Proposal Approval Committee at the Health Care Corporation of St. John's 
(Appendix D) approved this study. 
In order to provide questionnaire anonymity in the physicians' survey, identities 
were not requested and addresses were left off questionnaires and return envelopes. The 
reply post card sent separately permitted the responding physicians to remain anonymous, 
while allowing followup with non-responding physicians. Return of a completed 
questionnaire was considered implied consent for this group. 
3 Uptake rate was defined as the number of women who underwent MSS screening divided by the number 
of women who gave birth in the calendar year. 
4 Screen positive rate was defined as number of samples per I 00 that when analyzed had an unusual 
amount of the biochemical markers associated with it. 
5 Screen negative rate was defined as number of samples per I 00 that when analyzed had the usual amount 
ofthe biochemical markers associated with it. 
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To protect patient confidentiality and ensure first contact with potential 
participants was by someone perceived to be a third party, a MSA, approached potential 
participants to identify those interested. These women were given a patient questionnaire 
and envelope and were asked not to sign or report any identifying personal information. 
The MSA returned later in the day to pick up the completed questionnaire in a sealed 
envelope. This gave the patients time to read over the questionnaire and decide if they 
wanted to participate in the study. Return of a completed questionnaire was considered 
implied consent. 
To protect patient and physician confidentiality of MSS laboratory information, a 
third party, the Provincial Medical Genetics Program, provided statistical data. The data 
were kept in aggregate form and no identifying characteristics of either physician or 
patient were included in the data. 
All data were kept in a password protected computer in password protected files 
in a secure room. I was the only person with access to the data. 
Results are reported in aggregate form only. Individuals (physicians and patients) 
will not be identified in any publication or presentation. 
I will distribute the results to family physicians and obstetricians practicing in 
Newfoundland and Labrador. I will also share my results with the Provincial MSS 
Program and the Women ' s Health Centre in the Health Care Corporation of St. John's. 
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Chapter 4 - Results 
4.1 Physician Survey 
4.1.1 Response rate and sample representativeness 
Of the 525 eligible physicians listed on the Newfoundland and Labrador Medical 
Board mailing list, 40 physicians were ineligible because they had retired or moved. The 
remaining 485 physicians were found to be practicing family medicine or obstetrics. Of 
these 485 physicians, a total of293 physicians responded to the survey, 270 family 
physicians and 23 obstetricians, for an overall response rate of 60.4% (60.0% and 65.7% 
respectively). 
To assess representativeness, we compared the gender, specialty and location of 
practice of the respondents with the list provided by the Newfoundland and Labrador 
Medical Board (Table 4.1 ). 
According to the Newfoundland Medical Board's mailing list, 93.3 %of 
physicians were listed as family physicians and 6. 7 % were listed as obstetricians. These 
numbers were similar to those that responded to the survey, with 92.2 %reported 
practicing family medicine and the remaining 7.8% reported practicing obstetrics (Table 
4.1). 
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Table 4. 1 Representativeness of physicians who responded to the study 
NLMB Respondents 
n = 525 n = 293 
n (% ) n (%) 
Gender: 
Male 386 (73.5) 189 (64 .5) 
Female 139 (26 .5) 104 (35.5) 
Specialty: 
Family Medicine 490 (93.3) 270 (92.2) 
Obstetrician 35 (6.7) 23 (7.8) 
Location of medical practice: 
Rural 197 (37 .5) 125 (42.7) 
Semi Urban 50 (9.3) 29 (9.9) 
Urban 278 (53 .2) 139 (47.4) 
NLMB =Newfoundland and Labrador Medical Board 
According to the mailing list there were 386 (73.5 %) males and 139 (26.5 %) 
female practicing family medicine or obstetrics in the province at the time of the first 
mail-out. A greater proportion of female physicians returned the survey compared to 
male physicians (1 04/ 139 compared to 189/386 respectively). 
With regard to geographic distribution of the respondents, 125 (42.7 %) responses 
came from rural areas, 29 (9 .9 %) came from semi-urban areas and the remaining 139 
(47.4 %) came from urban areas. These numbers were found to be similar to those found 
on the mailing list obtained for the Newfoundland Medical Board (p < 0.05) . 
Eighty-eight of the respondents did not provide antenatal care in the past 12 
months and were therefore ineligible for the study. The study reports on the remaining 
205 physicians. 
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4.1.2 Physician Survey Respondents 
Table 4.2 presents the characteristics of the sample by specialty. The majority of 
both physician groups were males and between the ages of 40 and 59 (Table 4.2). There 
was a significant difference in the location of medical education between the two groups 
(p = 0.001 ). The majority of family physicians attended medical school in Canada, 
whereas the majority of obstetricians attended medical schools outside of Canada. As 
expected, family physicians were more widely distributed throughout the province, 
compared to obstetricians, who were concentrated in more urban areas. Obstetricians 
cared for significantly more pregnant women and performed significantly more deliveries 
than family physicians (p = 0.0001). Obstetricians, on average, cared for 152 pregnant 
women per year, whereas family physician cared for 25 pregnant women per year. With 
regards to deliveries, obstetricians performed on average 139 deliveries per year, whereas 
family physicians performed an average of 40 deliveries per year. 
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Table 4.2 Characteristics of physicians providing antenatal care in Newfoundland and Labrador 
Characteristic 
Male 
Female 
Medical Education 
in Canada 
outside Canada 
Age Group 
<30 
30 - 39 
40 - 49 
50 - 59 
60+ 
Mean years practicing 
in Canada (and SD) 
Practice Location 
Urban 
Semi urban 
Rural 
Practice Characteristics 
Perform deliveries 
No 
Yes 
# of deliveries 
(and SD) 
Mean no. of pregnant 
women cared for in 
past year (and SD) 
Mean no. of years 
providing antenatal 
care (and SO) 
Group; no. (%) of respondents 
Family physicians 
n= 182 
n (%) 
n = 180 
101 (56.1) 
79 (43.9) 
n = 182 
134 (73.6) 
48 (26.4) 
n = 181 
12 (6.6) 
50 (27.6) 
62 (34.3) 
48 (26.5) 
9 (5.0) 
n = 178 
16.5 +/-11.2 
n = 182 
79 (44.6) 
20(11.3) 
78 (44.0) 
n = 182 
155 (85 .2) 
27 (14.8) 
40.3 +/- 35.8 
n = 173 
25.4 +/- 25.9 
n = 175 
16.0 +/- I 0.0 
Obstetricians 
n = 23 
n (%) 
n = 21 
13 (61.9) 
8 (38.1) 
n = 23 
9 (39.1) 
14 (60.9) 
n = 20 
0 
3 (14.3) 
9 (42.9) 
8(38.1) 
I (4.8) 
n =21 
9.7 +/- 9.9 
n = 23 
14 (60.9) 
4 (17.4) 
5 (21.7) 
n = 23 
I (4.3) 
22 (95.7) 
139.5 +/- 47.9 
n = 22 
152.9 +/- 64.7 
n = 21 
16.1 +/- 8.9 
SO = standard deviation; * = statistically significant 
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value 
0.100 
0.001 * 
0.409 
0.008* 
0.042* 
0.000 
0.000 
0.000 
0.967 
4.1. 3 Physicians who do not offer MSS 
All the obstetricians who responded to the survey offered MSS to their patients. 
Of the 182 family physicians who provided antenatal care, 13.1% did not offer to MSS to 
their patients. Table 4.3 describes reasons chosen by physicians for not offering MSS. 
The majority of these physicians (58.3%) reported that they were unaware that MSS was 
available in Newfoundland and Labrador. Of the 23 family physicians who did not offer 
MSS, 60.9% practiced in rural areas and the remaining 39.1 %practiced in urban areas. 
Table 4.3 Opinion and practice location of physicians who provide antenatal care in Newfoundland 
and Labrador but who do not offer MSS. 
MSS Practice Characteristic 
Opinion of those who do not offer MSS 
Unaware MSS was available 
Creates undo anxiety in patients 
Follow up is difficult to coordinate 
Too many false positives 
Too difficult to explain test and outcomes 
Incompatible with my religious beliefs 
Too many false negatives/positives 
Too costly 
Too time consuming to explain 
Practice location: 
Urban 
Semi-Urban 
Rural 
4.1.4 Physicians who offer MSS 
Group; no.(%) ofrespondents 
Family physicians 
n = 23 
n (%) 
14 (58.3) 
6 (25.0) 
3 (I2.5) 
I (4.2) 
I (4.2) 
0 
0 
0 
0 
n = 23 
9 (39.1) 
0 
14 (60 .9) 
Table 4.4 describes the practice characteristics of physicians who offer MSS to 
their patients. A larger proportion of obstetricians (1 00%) than family physicians (86.8%) 
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offered MSS; 87.0% of obstetricians offered MSS to all patients, whereas 60.1% of 
family physicians reported offering MSS to all pregnant women. Overall, 46.7% of 
physicians were from urban areas, 13.9 % practiced in semi-urban areas and 3 9.4 % 
reported practicing in a rural area. 
Family physicians who offered MSS to only some women offered the screening 
test more often to women over the age of 35 at their due date and women with a family 
history of Down's syndrome or neural tube defect. 0 bstetricians reported that more 
women under the age of35 chose to undergo MSS when offered (46.6%), compared to 
the family physician group (34.6%). All obstetricians ordered MSS in the correct 
gestational time frame, as compared to 83.4% offamily physicians. When 
communicating screening results to patients, obstetricians communicated both positive 
and negative MSS results to patients in a shorter timeframe than family physicians, but 
this difference did not reach statistical significance. 
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Table 4.4 MSS practice characteristics of physicians who provide antenatal care in Newfoundland 
and Labrador. 
Group; no. (%)of respondents 
Family physicians 
MSS Practice Characteristic n = 158 
n (%) 
Practice location n = 155 
Rural 66 (41 .8) 
Semi-Urban 21(13.3) 
Urban 71(44.9) 
Women offered 1 n = 155 
All pregnant women 95 (60.1) 
Women age 35 or older 58 (36.1) 
Women under age 35 10(6.3) 
Women with family history of DS or NTD 58 (36.7) 
Women who asked to be tested 45 (28.5) 
Mean time spent discussing n = 155 
MSS with patient (minutes and SO) 7.7 +/- 5.2 
% of pregnant women <3 5 of age n= 130 
offered MSS chose to have it (% and SO) 34.6 +/- 34.2 
Physicians who ordered MSS at n = 145 
the correct gestational age 121 (83.4) 
(%) 
Communication of positive MSS results to patients 
Within 48 hours 
Within I week 
Within 2 weeks 
At next clinical appointment 
n = 158 
110(69.6) 
26 (16.5) 
7 (4.4) 
5 (3 .2) 
Communication of negative MSS results to patients 
n = 158 
Within 48 hours 21 (13.7) 
Within I week 24 (15.2) 
Within 2 weeks II (7.0) 
At next clinical appointment 96 (60 .8) 
Obstetricians 
n =23 
n (%) 
n =23 
5 (21.7) 
4 (17.4) 
14 (60.9) 
n =23 
20 (87.0) 
3 (13.0) 
0 
3 (13.0) 
4(17.4) 
n = 21 
9.2 +/- 4.4 
n =20 
46.6 +/- 31.4 
n = 23 
23 (100.0) 
n =23 
21 (91.3) 
0 
2 (8.7) 
0 
n=23 
5 (21.7) 
3 (13.0) 
0 
15 (65.2) 
value 
0.049* 
0.011 * 
0.033* 
0.366 
0.032* 
0.606 
0.150 
0.130 
0.046* 
0.091 
0.463 
OS= Down's syndrome; NTD =neural tube defect; SO = standard deviation; * = statistically significant 
1 Physicians could choose more than one group of women to whom they routinely offer MSS. 
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Table 4.5 describes the distance to MSS follow up services in hours. As expected 
family physicians reported longer distances to amniocentesis, level II ultrasound and 
genetic counseling follow up services, but these were not statistically significant. 
Table 4.5 Distances of health care providers in hours to follow up services for Maternal Serum 
Screening (MSS) 
Hours to MSS 
follow up services 
(and SD) 
Amniocentesis 
Level II ultrasound2 
Genetic Counseling 
Group; % of respondents 
Family physicians 
n= 165,165, 
160 
2.3 +/- 6.5 
2.1 +/- 5.8 
2.9 +/- 6.9 
Obstetricians 
n = 22, 21, 
22 
1.4 +/- 1.8 
1.6 +/- 2.9 
2.1 +/- 2.9 
Total 
n = 187, 186, 
182 
2.2 +/- 6.2 
2.0 +/- 5.5 
2.7 +/- 6.5 
p value 
0.160 
0.713 
0.347 
Table 4.6 describes physician knowledge ofthe false positive rate for MSS and 
the detection rates for the three prenatal diseases screened. Fewer than half (42.5%) of the 
family physicians correctly identified the false positive rate associated with MSS, as 
compared to 61.1% of obstetricians. Significantly more obstetricians than family 
physicians correctly identified the detection rate for Down's syndrome. The total 
respondents varied by question. 
2 Level two ultrasound is used to measure gestational age and fetal growth. The brain, heart, kidney, cord 
insertion, amniotic fluid volume, placental position and obvious maternal pelvic organ abnormalities are 
also noted. Level one ultrasound captures information about fetal number, fetal presentation, 
documentation of fetal life, placental location, assessment of amniotic fluid volume, assessment of 
gestational age, survey of fetal anatomy for gross malformations and an evaluation for maternal pelvic 
masses. 
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Table 4.6 Family physician and obstetrician knowledge of Maternal Serum Screening (MSS) 
characteristics 
MSS Knowledge 
Correctly identified MSS 
false positive rate (%) 
Correctly identified MSS 
detection rate for OS 
Correctly identified MSS 
detection rate for open NTD 
Group; % of respondents 
Family physicians 
n = 127, 129 
131 , 120 
n (%) 
54 (42.5) 
23 (17.8) 
53 (40.5) 
Obstetricians 
n = 18, 20 
17, 18 
n (%) 
II (61.1) 
9 (45.0) 
9 (52.9) 
value 
0.138 
0.006* 
0 .326 
Correctly identified MSS 44 (36.7) 5 (27.8) 0.462 
detection rate for Trisomy 18 
DS = Down 's syndrome; NTD = neural tube defect; * = statistically significant 
The following table (Table 4.7) describes where physicians reported hearing 
about MSS. A significantly larger proportion of obstetricians than family physicians 
reported hearing about MSS at hospital rounds and on the internet whereas, a 
significantly larger proportion of family physicians reported hearing about MSS from 
patients. 
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Table 4.7 Sources of information pertaining to Maternal Serum Screening (MSS) reported by 
physicians who provide antenatal care in Newfoundland and Labrador 
MSS information 
Medical I oumals 
Colleagues 
NL Medical Genetics Clinic pamphlet 
CME sessions 
Hospital rounds 
NLMA newsletter 
Patients 
Internet 
Newspapers 
Group; no.(%) of respondents 
Family 
physicians 
n = 182 
113 (62.1) 
98 (53 .8) 
94 (51.6) 
81 (44 .5) 
34 (18.7) 
36 (19.8) 
29 (15 .9) 
18(9.9) 
14 (7.7) 
Obstetricians 
n = 23 
19 (82.6) 
14 (60.9) 
9(39.1) 
15 (65 .2) 
II (47.8) 
3 (13 .0) 
0 
6 (26 .1) 
0 
Total 
n = 205 
132 (64.4) 
112 (54.6) 
103 (50.2) 
96 (46 .8) 
45 (22 .0) 
39(19.0) 
29 (14.1) 
24 (I 1.7) 
14 (6.8) 
p value 
0 .053 
0.524 
0.058 
0.061 
0.001 * 
0.438 
0.039* 
0.023* 
0.168 
CME = Continuing Medical Education; NL =Newfoundland and Labrador; NLMA =Newfoundland and 
Labrador Medical Association; * = statistically significant 
When obstetricians and family physicians were questioned about their practice of 
MSS in the past 18 months, the majority of both groups (63.6% and 69.6% respectively) 
responded that their MSS practice had not changed (Table 4.8). The majority of both 
groups (family physicians 70.8%, obstetricians 78 .9%) also reported that they would 
prefer a first trimester screening test rather than the present second trimester MSS test. 
There were no differences between obstetricians and family physicians when the two 
groups were asked ifMSS affects their medicolegal risk. Approximately equal 
proportions of each group (family physicians 33.1 %, obstetricians 30.4%) believed that 
MSS misleads their patient to believe that physicians can guarantee a healthy baby. 
Significantly more obstetricians than family physicians knew about the Provincial MSS 
Program. 
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Table 4.8 Family physician and obstetrician practice and opinion of Maternal Serum Screening 
(MSS) in Newfoundland and Labrador 
Characteristic 
MSS practice in the past 18 months 
Offer MSS more in past 18 months 
Offer MSS less in past 18 months 
No change in past 18 months 
Not sure 
MSS and medicolegal risk 
MSS increases medicolegal risk 
MSS decreases medicolegal risk 
MSS does not affect medicolegal risk 
Believe MSS misleads patients 
to believe physicians can 
guarantee a healthy baby 
Would prefer a 1st trimester 
screening test 
Aware ofProvincial MSS program 
Group; no. (%) of respondents 
Family physicians 
n = 185 
n (%) 
n= 173 
51 (29.5) 
5 (2.9) 
110(63.6) 
7 (4.0) 
n = 170 
41 (24. 1) 
43 (25.3) 
86 (50.6) 
n = 163 
54(33.1) 
n = 161 
114 (70.8) 
n = 168 
I 35 (80.4) 
* = statistically significant 
Obstetricians 
n = 23 
n (%) 
n =23 
5 (21.7) 
2 (8.7) 
16 (69.6) 
0 
n =22 
7 (3 1.8) 
8 (36.4) 
7 (31.8) 
n = 23 
7 (30.4) 
n = 19 
15 (78.9) 
n =23 
23(100.0) 
p value 
0.336 
0.249 
0.797 
0.456 
0.019* 
I also looked for differences between male and female physicians. As seen below, 
in Table 4.9, male physician respondents working in the province are significantly older 
and have been providing antenatal care for a significantly longer time than female 
respondents. Also, significantly more male physicians attended medical school outside of 
Canada. The two groups did not differ significantly in the number of women cared for, 
number of deliveries in the past twelve months nor in location of their practice. 
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Table 4.9 Practice characteristics of male and female physicians who provide antenatal care in 
Newfoundland and Labrador 
Group; no.(%) of respondents 
Female physicians Male physicians 
Characteristic n = 88 n = 115 
value 
n (%) n (%) 
Medical Education 
n = 88 n = 115 0.002* 
in Canada 71 (80.7) 70 (60.9) 
outside Canada 17(19.3) 45 (39.1) 
Age Group 
n = 85 n = 115 0.000* 
<30 4 (4.7) 8 (7.0) 
30-39 34 (40.0) 19 (16.5) 
40-49 34 (40.0) 37 (32.2) 
50 - 59 13 (15 .3) 41 (35.7) 
60+ 0 (0) 10 (8.7) 
Mean ~ears practicing n = 87 n = 114 
in Canada (and SD) 12 .8 +/- 9.1 17.6 +/- 11.7 0 .001* 
Practice Location 
n = 88 n = 115 0.343 
Urban 45(51.1) 46 (41.8) 
Semi urban 11 (12.5) 14 (12.7) 
Rural 32 (36.4) 50 (45.5) 
Practice Characteristics 
Perform deliveries 
n = 88 n = 115 
No 68 (77.3) 87 (75 .7) 
Yes 20 (22.7) 28 (24 .3) 0.461 
mean # of deliveries 70.3 +/- 60.3 84.0 +/- 66.8 0.474 
(and SO) 
Mean no. of pregnant n = 87 n = 115 0.192 
women cared for in 44.4 +/- 52.5 34.7 +/- 49.0 
past year (and SD) 
Mean no. ofyears n = 87 n = 113 0 .002* 
providing antenatal 13.4 +/- 8.2 17.8 +/- 10.5 
care (and SD) 
SD = Standard deviation ; * = statically significant 
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When MSS practices were analyzed further, it was found that female physicians 
offered MSS significantly more often to all their pregnant patients (Table 4.1 0) and 
within the correct timeframe. Females also reported positive screening results 
significantly more quickly to their patients than their male colleagues. The two groups 
did not differ in the time spent discussing MSS with patients nor in the percentage of 
patients under the age of 3 5 choosing to undergo the screening test. 
37 
Table 4.10 MSS practice characteristics of male and female physicians who provide antenatal care in 
Newfoundland and Labrador. 
Group; no. (%) of respondents 
Female physicians 
MSS Practice Characteristics n = 88 
n (%) 
Those who offer MSS: 
n = 88 
All pregnant women 64 (72 .7) 
Women age 35 or older 21 (23.9) 
Women under age 35 5 (5 .7) 
Women with family history ofDS or NTD 20 (22.7) 
Women who asked to be tested 16 (18 .2) 
Time spent discussing n = 86 
MSS with patient (min and SD) 8.0 (5.5) 
% ofpregnant women <35 of age n=72 
offered MSS chose to have it(% and SO) 33.1 (29.3) 
Physicians who ordered MSS at n = 81 
the correct gestational age 74 (91.4) 
(%) 
Communication of positive MSS results to patients 
n = 87 
Within 48 hours 69 (83.1) 
Within 1 week 13 (15 .7) 
Within 2 weeks I (1.2) 
At next clinical appointment 0 (0) 
Communication of negative MSS results to patients 
Within 48 hours 
Within I week 
With in 2 weeks 
At next clinical appointment 
n = 84 
9 (10 .7) 
18 (21.4) 
5 (6.0) 
52 (61.9) 
Male physicians 
n = 115 
n (%) 
n = 115 
65 (56.5) 
39 (33 .9) 
5 (4.3) 
41 (35 .7) 
33 (28.7) 
n = 90 
7.9 (4 .6) 
n = 78 
39.0 (38.3) 
n = 87 
70 (80.5) 
n = 93 
60 (69 .0) 
14 (16.1) 
8 (9.2) 
5 (5.7) 
n = 90 
15 (16 .7) 
10(11.1) 
6 (6 .7) 
59 (65 .6) 
value 
0 .000* 
0.125 
0.749 
0.063 
0.099 
0 .875 
0.298 
0.049* 
0.012* 
0.249 
DS = Down ' s syndrome, NTD = neural tube defect, SO = standard deviation; * = statistically significant 
As seen below in Table 4.11, male and female physicians did not differ 
significantly in their knowledge of MSS screening rates . The majority of female 
physicians (50.7%) reported the correct false positive rate associated with MSS, 
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compared to 40.3% of male physicians. Male and female physicians scored very similarly 
with regard to correctly identifying the detection rates for the three genetic abnormalities 
screened for by MSS. Total respondents varied by question. 
Table 4. 11 Male and female physician knowledge of Maternal Serum Screening (MSS) 
MSS Knowledge 
Characteristic 
Correctly identified MSS 
false positive rate(%) 
Correctly identified MSS 
detection rate for DS 
Correctly identified MSS 
detection rate for open NTD 
Correctly identified MSS 
detection rate for Trisomy 18 
Group; %of respondents 
Female physicians Male physicians 
n = 75, 63, n=67,84, 
64,64 82, 72 
38 (50.7) 27 (40.3) 
14 (22.2) 18 (21.4) 
25 (39.1) 36 (43 .9) 
23 (35.9) 26 (36.1) 
value 
0.240 
1.000 
0.614 
1.000 
When physicians were asked about their MSS practice in the past 18 months 
(Table 4.12), approximately one-quarter of male and female physicians reported that they 
offered MSS more often at the time of the survey (26.6% and 30.6% respectively). Both 
groups were evenly split on the influence MSS had on their medicolegal risk. 
Approximately half of physicians thought that MSS had no affect on their medicolegal 
risk, while the remaining physicians were split between whether MSS increased or 
decreased their risk. The two groups did, however, differ significantly on whether MSS 
misleads patients to believe that physicians could guarantee a healthy baby. A larger 
proportion of male physicians than female physicians reported that MSS misleads 
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patients. Lastly, a significantly larger percentage of female physicians were aware ofthe 
Provincial MSS Program than their male colleagues. 
Table 4.12 Male and female physician practice characteristics and opinion of Maternal Serum 
Screening (MSS) 
Characteristic 
MSS practice in the past I 8 months 
Offer MSS more in past I 8 months 
Offer MSS less in past 18 months 
No change in past I 8 months 
Not sure 
MSS and medicolegal risk 
MSS increases medicolegal risk 
MSS decreases medicolegal risk 
MSS does not affect medicolegal risk 
Believe MSS misleads patients 
to believe physicians can 
guarantee a healthy baby 
Would prefer a I •• trimester 
screening test 
Group; no. (%) ofrespondents 
Female physicians 
n = 85 
n (%) 
n = 85 
26 (30 .6) 
2 (2.4) 
57 (67.1) 
0 
n = 83 
21 (25 .3) 
I 9 (22 .9) 
43 (5 1.8) 
n = 80 
18 (22.5) 
n = 75 
55 (73 .3) 
Male physicians 
n = 115 
n(%) 
n = 109 
29 (26.6) 
5 (4.6) 
68 (62.4) 
7 (6.4) 
n = 108 
28 (25 .9) 
30 (27 .8) 
50 (46.3) 
n = 104 
42 (40.4) 
n = 105 
74 (70.5) 
value 
0.088 
0.692 
0 .0 I I* 
0.456 
Aware of Provincial MSS program n = 80 
75 (93 .8) 
n = 109 
81 (74.3) 
0.000* 
* = statistically significant 
Table 4.13 describes the personal and practice difference between family 
physicians who offer MSS to all their patients, family physicians who offer MSS to some 
of their patients, and those family physicians who do not offer MSS to their patients. As 
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noted below, there was a significantly larger proportion of male family physicians who 
do not offer MSS as compared to their female peers. The two groups of family physicians 
that offer MSS are younger in age than the group of family physicians who do not offer 
MSS. A larger percentage of family physicians in rural areas offered the screening test 
less often than their urban peers. 
Also, the family physicians who did not offer MSS cared for significantly fewer 
pregnant women in the past year and also delivered fewer babies. The Boneferroni test 
found that family physicians who offered MSS to some or all did not differ significantly 
(p = 0.802). There was also no difference (p = 0.130) between family physicians who 
offered MSS to some and those that did not offer the screening test to their patients. 
Those who offered MSS to all their patients did differ significantly (p = 0.0 12) to 
physicians who did not offer MSS. 
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Table 4.13 Demographic and clinical characteristics of family physicians who offer MSS to all, some, 
or none of their patients 
Group; no. (%)of respondents 
Family physicians Family physicians Family physicians 
who offer MSS to who offer MSS who do not offer 
all patients to some patients MSS to patients 
Characteristic n=103(%) n = 63 (%) n = 24 (%~ E value 
Sex n = 95 n = 63 n = 24 0.000* 
Male 39(41.5) 39 (62 .9) 23 (95 .8) 
Female 55 (58 .5) 23 (37 .1) 1 (4.2) 
Medical Education n = 95 n = 63 n = 24 0.000* 
in Canada 81 (85 .3) 41(65.1) 12 (50 .0) 
outside Canada 14 (14.7) 22 (34.9) 12 (50.0) 
Age Group n = 94 n = 63 n=24 0.048* 
<30 3 (3 .2) 7(11.1) 2 (8.3) 
30-39 38 (40.4) 8 (12.7) 4 (16.7) 
40 - 49 26 (27.7) 31 (49.2) 5 (20.8) 
50 - 59 23 (24.5) 16 (25 .4) 9 (37.5) 
60+ 4 (4.3) 1 ( 1.6) 4 (16 .7) 
Mean years Qracticing n=92 n= 62 n =24 0.162 
in Canada (and SO) 14.3 +/-10 .1 15 .9 +/- 10.0 19.8 +/- 13 .5 
Practice Location n = 93 n = 61 n =23 0.046* 
Urban 47 (50.5) 23 (37 .7) 9 (39.1) 
Semi urban 11 (11.8) 9 (14.8) 0 
Rural 35 (37.6) 29 (47 .5) 14 (60 .9) 
Practice Characteristics 0.309 
Perform deliveries n = 95 n = 63 n = 24 
No 80 (84.2) 52 (82.5) 23 (95 .8) 
Yes 15 (15 .8) 11 (17.5 I (4.2) 
# of deliveries (and SO) 42.3 +/- 40 .9 41.2 +/- 28.7 1 0.345 
Mean no . of n = 90 n = 61 n = 22 0.016* 
pregnant women 29.3 +/- 26 .2 24.6 +/- 28 .1 11.7 +/- 7.8 
cared for in the 
past year (and SO) 
Mean no . of years n = 91 n = 61 n = 23 0.094 
providing antenatal 14.4 +/- 9.9 17.0 +/- 9.0 19.9 +/- 12.0 
care (and SO) 
Time spent n = 93 n = 62 0.318 
discussing MSS 7.3 +/- 4.5 8.2 +/- 6.1 nla 
with patient (and SO) 
% of pregnant n = 91 n = 63 0.000* 
women <35 of age 46.2 +/- 34 .2 14.0 +/- 22.9 nla 
offered MSS choose 
to have it (% and SO) 
SO = standard deviation; * = statistically significant 
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Table 4.14 compares the MSS practices and opinions of family physicians who 
offer MSS to all their patients, family physicians who offer MSS to some of their patients 
and those family physicians who do not offer MSS to their patients. There was a 
significant difference in MSS practice in the past 18 months among the family physician 
groups. A larger percentage of physicians who do not offer MSS had not changed their 
MSS practices in the past 18 months than the other two family physician groups. A larger 
percentage of family physicians who offered MSS to some or all patients were more 
likely to have reported offering MSS more in the past 18 months than those family 
physicians who did not offer MSS. 
A larger proportion of family physicians (58.3%) who did not offer MSS were 
unaware of the Newfoundland and Labrador MSS Program. There was no difference in 
attitudes about medico-legal risks among the three groups of physicians. 
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Table 4.14 MSS practice and opinion characteristics of family physicians who provide antenatal care 
in Newfoundland and Labrador. 
Group; no.(%) ofrespondents 
Family physicians Family physicians Family physicians 
who offer MSS to who do offer MSS who do not offer 
all patients to all patients MSS to patients 
Characteristic n = 103 n = 63 n=24 E value 
n (%) n (%) n (%) 
MSS gractice in the gast 18 months 
n = 103 n=61 n = 22 0.026* 
Offer MSS more 32 (3l.l) 14 (23.0) 0 
Offer MSS less 14 (13.6) 4 (6.6) 0 
No change 57 (55.3) 40 (65.6) 19 (86.4) 
Not sure 0 3 (4.9) 3 (13 .6) 
MSS and medicolegal risk 
n = 89 n =62 n = 19 0.943 
MSS increases risk 23 (25.8) 13 (21.0) 5 (26.3) 
MSS decreases risk 19(21.3) 21 (33.9) 3 (15.8) 
MSS does not affect 47 (52 .8) 28 (45.2) 11 (57.9) 
risk 
Believe MSS misleads n = 85 n = 60 n = 18 0.132 
patients to believe 22 (25 .9) 23 (38.3) 9 (50.0) 
physicians can 
guarantee a healthy 
baby 
Would prefer a I st n = 83 n =57 n =21 0.725 
trimester screening 57 (68.7) 40 (70.2) 17 (81.0) 
test 
Aware of Provincial n = 88 n =59 n = 21 0.000* 
MSS ~ro~ram 81 (92.0) 47 (79.7) 7 (33.3) 
* = statistically significant 
The physician survey concluded with an open-ended question on the physicians' 
opinions of the MSS program. The majority of physicians (61.4%) took the opportunity 
to express their views and opinions on the MSS program; 45.2% of physicians who 
responded to this question thought that the MSS program was beneficial with many 
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describing the program as "excellent". Some physicians used this question to complain 
about MSS, 7.9% wrote that MSS distressed patients, 8.7% thought the false positive 
screening rate was too high, and 6.3% thought that patients had no interest in the 
screening test. Physicians were also asked if they had any comments they wanted to 
share. This second open-ended question had a very low response rate as the majority of 
physicians used the first open-ended question to express their thoughts and opinions of 
the Provincial MSS Program. 
4.2 Patient Survey 
Ofthe 300 surveys handed out, 200 patients returned the survey complete for a 
total response rate of 66. 7%. The average age of mothers who delivered between October 
8th and November 27th of2003 was 29.1 years (Table 4.15). 
Table 4.15 presents the demographic characteristics and MSS knowledge of the 
women surveyed. The majority of women were 35 years of age or younger (84.5%) and 
lived in urban areas (55.1 %). Almost all women (95.5%) reported visiting a physician 
between 15 and 20 weeks gestation. Among women surveyed, 45.3% reported discussing 
the screening test with their family physician while 24.1% reported discussing MSS with 
their obstetrician. 
Of the 117 women who discussed MSS with a physician, 54 (46.2%) chose to 
undergo MSS screening. Therefore, 54 of the 200 women surveyed underwent MSS, for 
an overall MSS uptake rate of27.0%. 
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Table 4.15 Characteristics among women who gave birth and their experiences with MSS. 
Characteristic 
Age: 
<25 years 
25-30 years 
31-35 years 
> 35 years 
average age (and SD) 
Location of residence: 
Urban 
Semi urban 
Rural 
Familiar with MSS: 
Source of information: 
Family Physician 
Obstetrician 
Not aware of MSS 
Friends or family 
Media 
Public Health Nurse 
Saw a physician between 15-20 weeks: 
No or Don't Know 
Yes 
MSS discussed 
Time physicians spend discussing MSS (and SD) 
Underwent MSS 
Underwent Amniocentesis 
Underwent Ultrasound 
Group; no.(%) ofrespondents 
Patients 
0 = 200 
n (%) 
n=200 
45 (22.5) 
56 (28.0) 
68 (34.0) 
31 (15.5) 
29.1 +/- 5.2 
n= 196 
108 (55.1) 
15 (7.7) 
73 (37.2) 
n = 200 
139 (69.5) 
n =200 
92 (46.0) 
49 (24.5) 
52 (26.0) 
24 (12.0) 
9 (4.5) 
5 (2.5)' 
n = 200 
11 (5.5) 
189 (94.5) 
117 (62.9) 
8.6 +/-8.1 
54 (31.8) 
13 (6.4) 
197 (98 .5) 
SD = Standard deviation 
As seen in Table 4.16 women undergoing MSS were significantly older than 
women who did not undergo the screening test. A larger percentage of these women 
46 
discussed MSS with their family physician or obstetrician between 15 and 20 weeks of 
their pregnancy. 
Table 4.16 Characteristics of women who underwent MSS and who did not undergo MSS 
Characteristic 
Average age (and SD) 
Location of residence: 
Urban 
Semi urban 
Rural 
Familiar with MSS 
Source of MSS Info: 
Family Physician 
Obstetrician 
Not aware of MSS 
Friends or family 
Media 
Public Health Nurse 
Saw a physician between 15-20 weeks: 
No or Don't Know 
Yes 
MSS discussed 
Minutes MSS was discussed 
Would undergo MSS again 
Underwent Amniocentesis 
Underwent Ultrasound 
Screening result: 
Don't know 
Screen negative 
Screen positive 
Underwent Counseling: 
Genetic Counselor 
Family Physician 
Obstetrician 
Psychologist 
Group; no.(%) of respondents 
Patients who 
underwentMSS 
n =53 
n =53 
32.0 +/- 4.9 
n =52 
28 (53.2) 
6 (I 1.5) 
18 (34.6) 
n =53 
52 (98.1) 
n =53 
33 (62.3) 
25 (47.2) 
0 
6 (11.3) 
0 
0 
n =53 
0 
53 (100) 
50 (100) 
9.96 +/- 10.4 
34 (79.1) 
6(11.3) 
52 (98.1) 
n =52 
I ( 1.9) 
42 (80.8) 
9 (17.3) 
n =53 
7 (13.2) 
4 (7.5) 
3 (5.7) 
0 
Patients who did 
not undergo MSS 
n = 147 
n = 147 
29.4 +/- 5.1 
n = 144 
80 (55.6) 
9 (6.3) 
55 (38.2) 
n = 147 
87 (59.2) 
n= 147 
59 (40.1) 
24 (16.3) 
52 (35.4) 
18 (12.3) 
9(6.1) 
5 (3.4) 
n = 147 
11 (7.5) 
136 (92.5) 
67 (49.3) 
7.38 +/- 5.4 
n/a 
7 (4.8) 
145 (98.6) 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
SD = Standard deviation; * = statistically significant 
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p value 
0.002* 
0.002* 
0.461 
0.000* 
0.006* 
0.000* 
0.000* 
0.859 
0.065 
0.174 
0.123 
0.000* 
0.113 
0.097 
0.787 
Table 4.17 describes the women surveyed by age categories. It was found that a 
larger percentage of women in the older age categories were familiar with and had 
undergone MSS. These older age categories reported that family physicians were an 
important source ofMSS information. A larger percentage of women in the older age 
categories also reported undergoing amniocentesis than women in younger age 
categories. 
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4.17 Characteristics by age groups of the patient study population. 
Characteristic 
Location of residence: 
Urban 
Semi urban 
Rural 
Familiar with MSS 
Source of MSS Info: 
Family Physician 
Obstetrician 
Not aware ofMSS 
Friends or family 
Media 
Public Health Nurse 
Saw a ghysician between 15-20 weeks: 
No or Don't Know 
Yes 
MSS discussed 
Minutes MSS was discussed (SD) 
Chose not to undergo MSS 
Don't Know 
Underwent MSS 
Would undergo MSS in next pregnancy 
Underwent amniocentesis 
Underwent ultrasound 
Screening result: 
Don't know 
Screen negative 
Screen positive 
Underwent Counseling 
Genetic Counselor 
Family Physician 
Obstetrician 
Group; no. (%) ofrespondents 
< 26 
years 
old 
n=45 
n =43 
24 (55.8) 
4 (9 .3) 
15 (34.9) 
22 (48.9) 
n =45 
10 (22.2) 
II (24.4) 
19 (42.2) 
5 (11.1) 
3 (6.7) 
3 (6.7) 
n =45 
8 (17.7) 
37 (82.2) 
14 (35.0) 
7.7 +/- 4.5 
26 (66.7) 
7(17.9) 
6 (15.4) 
5 (71.4) 
2 (4.4) 
44 (97.8) 
n=6 
0 
6 (100) 
0 
0 
0 
0 
0 
26-30 
years 
old 
n =55 
n =54 
24 (44.4) 
4 (7.4) 
26 (48.1) 
35 (63.6) 
n =55 
26 (47.3) 
9 (16.4) 
18 (32.7) 
8 (14.5) 
3 (5.5) 
0 
n =55 
3 (5 .5) 
52 (94.5) 
26 (54 .2) 
7.2 +/- 6.2 
31 (63.3) 
5 (10.2) 
13 (23.2) 
10 (83.3) 
0 
53 (96.4) 
n = 13 
0 
12 (92.3) 
I (7.7) 
0 
0 
0 
0 
31-35 
years 
old 
n=69 
n = 68 
40 (58.8) 
5 (7 .4) 
23 (33 .8) 
56 (81.2) 
n = 69 
38 (55.1) 
17 (25 .0) 
13 (18.8) 
8(11.6) 
3 (4.3) 
2 (2.9) 
n = 69 
0 
69 (100) 
50 (73.5) 
7.5 +/- 5.0 
43 (65 .2) 
I ( 1.5) 
21 (30.9) 
15 (75 .0) 
6 (8.7) 
69 (I 00) 
n =24 
1(4.2) 
19 (79.2) 
4(16.7) 
4(1 00) 
4(1 00) 
2(50.0) 
2 (50.0) 
SD = Standard deviation ; * = statistically significant 
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> 35 
years 
old 
n = 31 
n = 31 
20 (64.5) 
2 (6.5) 
9 (29.0) 
26 (83.9) 
n = 31 
18 (58.1) 
12 (38.7) 
2 (6.5) 
3 (9.7) 
0 
0 
n = 31 
0 
31(100) 
27 (90.0) 
p value 
0 .600 
0 .001 * 
0 .002* 
0.148 
0.001 * 
0 .910 
0.557 
0.141 
0.002* 
0.000* 
12.1 +/- 13.5 0.193 
16(53.3) 
I (3 .3) 
13 (41.9) 0.017* 
8 (61.5) 0.667 
5 (16.1) 0.024* 
31 (100) 0.337 
n = 13 0.129 
0 
7 (53.8) 
6 (46.2) 
6 (100) 0.004* 
4 (66 .7) 0.011 * 
3 (50.0) 0.027* 
2 (33.3) 0.141 
Table 4.18 describes the women surveyed by the size of the community in which 
they reside. It was found that a larger percentage of women in semi-urban areas were 
unsure if they had undergone MSS. 
4.18 Characteristics by size of residence community among women surveyed. 
Group; no. (%) of respondents 
Characteristic 
Average age (and SD) 
Familiar with MSS 
Source ofMSS Info: 
Family Physician 
Obstetrician 
Not aware of MSS 
Friends or family 
Media 
Public Health Nurse 
Saw a Rhysician between 15-20 weeks: 
No or Don' t Know 
Yes 
Underwent Amniocentesis 
MSS discussed 
Minutes MSS was discussed (and SD) 
Chose not to undergo MSS 
Don't Know 
Underwent MSS 
Urban 
n = 108 
n = 108 
30.6 +/- 5.5 
n = 108 
75 (69.4) 
n = 108 
49 (45.4) 
26 (24.1) 
31 (28.7) 
14(13.0) 
5 (4 .6) 
3 (2 .8) 
n = 108 
3 (2.8) 
105 (96.2) 
II (10.2) 
65 (61.9) 
9.31 +/- 9.4 
64 (66 .0) 
3 (3 .1) 
30 (30 .9) 
Would undergo MSS in next pregnancy 24 (75 .0) 
Screening result: n = 32 
Don' t know 1 (3 .1) 
Screen negative 24 (75 .0) 
Screen positive 7 (21.9) 
Underwent Counseling: n = 7 
Genetic Counselor 5 (71.4) 
Family Physician 3 (42 .9) 
Obstetrician I (14.3) 
Semi-urban 
n = 15 
n = 15 
29.6 +/- 5.3 
n = 15 
I 0 (66.7) 
n = 15 
9 (60.0) 
3 (20) 
4 (26.7) 
2(13.3) 
0 
1(6.7) 
n = 15 
I (6.7) 
14 (93 .3) 
1 (6 .7) 
9 (69.2) 
9.50 +/- 8.9 
5 (33.3) 
4 (26.7) 
6 (40.0) 
1 (25 .0) 
n = 6 
0 
3 (50.0) 
3 (50.0) 
m = 3 
2 (66.7) 
1 (33 .3) 
2 (66. 7) 
Rural 
n = 73 
n = 72 
29 .6 +/- 4 .7 
n = 73 
51 (69.9) 
n = 73 
33 (45 .2) 
19 (26.0) 
16 (21.9) 
8 (11.0) 
3(4. 1) 
I (1.4) 
n = 73 
6 (8 .2) 
67 (91.8) 
1 (1.4) 
41 (64 .1) 
7.39 +/- 5.8 
45 (65.2) 
7 (10. 1) 
17 (24.6) 
12 (80 .0) 
n = 17 
0 
16 (94 .1) 
1 (5.9) 
n = l 
I (100) 
1 (20.0) 
I ( 100) 
SD = Standard deviation ; * = statistically significant 
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p value 
0.757 
0.970 
0.548 
0.875 
0.593 
0.914 
0.697 
0.483 
0.336 
0.065 
0 .861 
0.369 
0.089 
0.035* 
0.461 
0 .080 
0.173 
0.094 
0.483 
0.006* 
As seen in the table below, a larger proportion of patients in every community 
size visited a family physician between 15 and 20 weeks of gestation as compared to 
those visiting obstetricians. Regardless of type of physician seen or where the patient 
lived, MSS was discussed with the majority of patients. Although a greater proportion of 
patients in each area reported discussing MSS with their obstetrician than with their 
family physician (Table 4.19). 
Table 4.19 Patients who visited physicians between 15 and 20 weeks of their pregnancy and their 
experiences with Maternal Serum Screening (MSS) by place of residence 
Group; no.(%) ofrespondents 
Urban Semi-urban Rural Total 
Between 15 and 20 
weeks of pregnancy p value 
Visited Family Physician n = 77 n = 10 n =52 n = 139 0.169 
MSS discussed 
No or Can't remember 33 (42.8) 5 (50.0) 21 (40.4) 59 (42.5) 
Yes 44 (57.1) 5 (50.0) 31 (59.6) 80 (57.6) 
# ofmin(and SD) 8.0 +/- 6.7 12.5 +/- 11.9 7.0 +/- 5.4 7.7 +/- 6.5 0.284 
underwent MSS 21 (47.7) 5 (100) 12 (38.7) 8 (47.5) 0.002* 
Visited Obstetrician n=41 n=9 n = 31 n = 81 0.613 
MSS discussed 
No 10 (24.4) I (11.1) 6(19.4) 17 (21.0) 
Can ' t remember l (2.4) 0 4 (12.9) 5 (6.2) 
Yes 30 (73 .2) 8 (88.8) 21 (67.7) 59 (72.8) 
# ofmin(and SD) 10.8 +/- 11.1 6.6 +/- 3.5 9.1 +/- 6.0 9 .6 +/-8 .9 0.625 
underwent MSS 14 (46.7) 5 (62 .5) 10 (47.6) 29 (49 .2) 0.447 
SD = Standard Deviation; * statistically significant 
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4. 3 Laboratory Data 
The table below describes actual physician use of MSS in 2003, obtained from the 
Provincial MSS Program. A total of355 different physicians ordered the screening test at 
least once. The majority of physicians (53.2%) practiced in rural areas, with a little over a 
third (37.5%) practicing in urban areas. 
Table 4.20 Physician use of MSS reported by the Newfoundland and Labrador MSS Program 
for 2003 
Practice Location 
Urban 
Semi-Urban 
Rural 
Total 
Physicians using MSS (%) 
n (%) 
133 (37.5) 
33 (9.3) 
189 (53.2) 
355 (100) 
There were 1049 samples received by the Provincial Maternal Serum Screening 
Program in 2003; 66 samples were received too early and 13 samples were received too 
late. Subtracting these 79 samples that were received outside the 15 to 20 gestational 
week timeframe ofMSS, there were 970 (92.5%) samples that were ordered within the 
correct time and analyzed. 
Using the total births of20023 (Newfoundland and Labrador Centre for Health 
Information, 2003), 970 out of a possible 4860 possible women were analyzed, giving an 
overall 22% MSS uptake rate. 
3 The total births for 2003 are currently not available. 
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Table 4.21 describes the false positives associated with the MSS as reported by 
the Provincial MSS Program. There were no true positives encountered by the Program in 
the year of 2003 and the overall false positive rate was 13.1 %. 
Table 4.21 False Positives reported by the Newfoundland and Labrador MSS Program for 2003 
Practice Location 
Open Neural Tube Defects 
Down's Syndrome 
Trisomy 18 
Overall false positive rate 
Samples from women < 35.5 years old 
Samples from women> 35.5 years old 
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False Positives 
n(%) 
28 (2.9) 
95 (9.8) 
4 (0.4) 
13.1 
52 (5.9) 
46 (32.6) 
Chapter 5 -Discussion 
5.1 MSS Rates 
Our study found that 88.8% of physicians were offering MSS screening to 
their patients. Of the physicians who were offering MSS, 63.5% were found to be 
offering MSS to all patients. The remaining 36.5% were offering MSS to selective 
groups of patients (women who asked to be tested or groups of women considered 
to be "high risk"). 
Twenty-seven percent of the patients surveyed underwent MSS, 62.9% 
reported that they had discussed MSS when they visited a physician between 15 
and 20 weeks and 46.2% of these patients chose to undergo MSS. 
Information obtained from the Provincial MSS Program confirmed that the 
MSS uptake rate in Newfoundland and Labrador was 22%. This rate compares to 
48% in Ontario (Summers, 2003) and 68% in Manitoba (Karen MacDonald, 
Personal Communications, April 29, 2004). Internationally, these uptake rates 
compare to 65% of pregnant women who underwent maternal serum screening in 
France in 1998 (Muller, 2002). 
In a survey ofNewfoundland and Labrador physicians in 2000, Chandra et 
al. (2003) found that only 29% of physicians were offering MSS to all patients. 
Our study found nearly 65% of responding physicians were offering MSS to all 
their patients. However, there are still fewer physicians offering MSS to all 
patients compared to other provinces in Canada. In a similar study done in 
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Ontario, Carroll et al. (1997) discovered that 88% of health care providers were 
offering MSS to all pregnant women, compared to 63% in Newfoundland and 
Labrador. 
The overall improvement in the number of physicians offering MSS to 
women may be attributed to the MSS promotional and educational sessions held 
across the province in 2002. Promotion included television, radio and newspaper 
spots. MSS education was done by a public health nurse who traveled across the 
province holding MSS educational sessions in every hospital that performed 
deliveries. 
There has been an improvement in the number of physicians offering 
MSS, but there are still many physicians offering the screening test selectively to 
only certain groups of women. There is, therefore, still much education and 
promotion to be done with this screening tool. 
5. 2 Who is being offered MSS 
Our study discovered that there were three types of physicians with regard 
to MSS practice: those who offered MSS to all patients; those who offered MSS 
to selected groups of patients; and those who did not offer MSS. Eighty-seven 
percent of obstetricians offered MSS to all patients. Significantly fewer family 
physicians offered MSS to all their patients; 52.2% of family physicians offered 
MSS to all women and 34.6% offered MSS selectively to their patients. The 
remaining 13.2% of family physicians did not offer MSS. 
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Therefore, a total of 47.8% of family physicians reported either not using 
MSS or offering it to selected groups of women [including women who asked to 
be tested and/or those considered to be at "high risk" (women over the age of 35 
years old and/or those with a family history of Down's syndrome or open NTD)]. 
Of all patients who visited a physician between 15 and 20 weeks, a total of 
31 .8% underwent the prenatal screening test. The concept of selective MSS 
screening was also seen in this portion of our study. There was a significant 
difference among the age categories of women who were familiar with MSS. 
Forty-eight percent of the women surveyed under the age of26 were familiar with 
MSS; this compares to nearly 84% ofwomen who were over 35 years of age. 
Significantly larger proportions of women in older age groups reported that their 
family physician discussed MSS with them and significantly larger proportions of 
older women chose to have the MSS test. 
The relationship between knowledge of MSS and age was also found in a 
study done in Ontario (Goel et al. , 1998). Goel et al. evaluated patient knowledge 
of MSS using a MSS knowledge questionnaire. The investigators discovered that 
MSS knowledge was correlated positively with age. A woman's likelihood of 
carrying a fetus with a genetic abnormality increases with age. This is well known 
among physicians and among women of child-bearing age. Women over the age 
of 3 5 therefore tend to be more informed regarding birth defects and the prenatal 
tests available. 
MSS uses population-based risk ratios and it is therefore inappropriate to 
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recommend MSS solely to women in high risk groups. The results that nearly 
50% of family physicians are offering MSS to selective groups of women are a 
cause of concern for the Provincial MSS Program, as MSS is intended to be a 
population based screening tool. Risk rates are calculated by comparing the 
analyzed biochemical marker levels to levels typically seen in the general 
population. It is, therefore, evident that the message that all women should be 
offered MSS screening is not known throughout the health care and general 
community. 
5. 3 Who is offering MSS 
Our study found that a larger percentage of obstetricians than family 
physicians were offering MSS to all patients. Obstetricians cared for significantly 
more pregnant women and performed more deliveries, on average, than family 
physicians. 
These findings are consistent with the two different fields of medicine. 
Obstetrics is the branch of medicine specializing in pregnancy, labour, and the 
period immediately following childbirth. Family physicians do not typically 
specialize in one aspect of medicine. They are primary care providers and often 
serve as the first point of contact patients have with the health care system. 
Obstetricians receive more education and experience in prenatal care and would 
therefore have more exposure to prenatal disease and high risk pregnancies. 
Physicians who were offering MSS to all their patients were more often 
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younger, female and graduates of medical school in Canada. This would seem to 
make sense as MSS is a relatively new prenatal screening test, being first 
introduced in Canada in 1993. MSS would be more familiar to recent medical 
school graduates and, therefore, younger physicians. These advances in prenatal 
screening may not have been offered in foreign countries and therefore may not 
have been emphasized in foreign medical schools. Chandra et al (2003) similarly 
found in her 2000 survey of Newfoundland and Labrador physicians that female 
physicians were more likely to offer MSS. 
Screening seemed to be related to how often the physician encountered the 
issues surrounding the screening test- how relevant prenatal diseases were to the 
physician's practice. Difference in MSS practice among obstetricians and family 
physicians is of particular importance in our province. Women in Newfoundland 
and Labrador are typically under the care of a family physician until the third 
trimester of pregnancy. Consequently, by the time a pregnant woman visits an 
obstetrician it is too late to order MSS. The majority of patients will depend on 
their family physician for MSS screening. It is therefore essential that family 
physicians discuss all the available prenatal testing options with their patients. 
5. 4 Who is not offering MSS 
Eleven percent of physicians were not offering MSS to their patients. All 
of these physicians (n = 23) were family physicians and accounted for 13.7% (n = 
23) of the total family physician respondents providing antenatal care in the past 
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twelve months. These physicians more often attended medical school outside of 
Canada, were older and had cared for significantly fewer pregnant women in the 
past twelve months. 
The majority (58.3%) of family physicians who reported not offering MSS 
to their patients reported that they were unaware that the screening test was 
available in Newfoundland and Labrador. We found that fewer physicians were 
not offering MSS since the study done by Chandra et al. (2003). Chandra 
discovered in her 2000 survey of physicians that 16% of physicians were not 
offering MSS to their patients. 
Offering MSS may, therefore, be related to training. This point 
underscores the need for Continuing Medical Education for all physicians, 
specifically surrounding new tests that become available in the province. 
5. 5 Urban and rural differences 
There was no difference in MSS use among women from urban and rural 
areas. However, among women who visited a family physician between 15 and 20 
weeks, a significantly larger percentage of women living in semi-urban areas had 
MSS than women living in either urban or rural areas. This finding was supported 
in the physician survey of our study which found that all physicians in semi-urban 
areas providing antenatal care offered MSS. 
This finding also suggests that the uptake of MSS is not an access issue. It 
may be explained by local physicians taking an active role in MSS promotion. A 
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theory proposed by Dixon ( 1990) explains that the adoption or promotion of a 
new genetic test by professional leaders in smaller communities may have a 
greater effect on diffusion in those communities than announcements of consensus 
on the part of nationally prominent physicians and scientists that a new technology 
should be adopted. This is of particular importance in Newfoundland and 
Labrador, as there are a large number of small communities located throughout 
the province. If MSS screening is to become widespread throughout the 
Newfoundland and Labrador, it would seem that local physicians should be of 
primary importance in the introduction and promotion of the screening test. 
5. 6 Physician knowledge and attitude towards MSS 
Physicians did not know the particular detection rates or false positive 
rates associated with MSS. However, the physicians who used the screening test 
ordered it more often within the 15 to 20 gestational week timeframe and also 
reported positive screening results back to patients more quickly. 
Obstetricians ordered MSS more often within the correct timeframe of 15 
to 20 weeks. Obstetricians also reported positive MSS screening results back to 
patients more quickly than family physicians. The risk associated with MSS relies 
heavily on the correct dating of the gestational age of the fetus. Errors in 
gestational age estimates are the single largest contributor to inaccuracies of risk 
estimation (Carroll, 1997). Therefore ordering MSS within the correct timeframe 
and allowing patients enough time to have follow-up ultrasound (used to verify 
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the actual gestational age) is very important to this screening test. 
The data obtained from the Provincial Medical Genetics clinic supported 
the point that most physicians were ordering MSS within the correct timeframe; 
92.5% of samples obtained from physicians were within the acceptable time of 15 
to 20 gestational weeks. This information also indicates that 7.5% of physicians 
are currently ordering the screening test incorrectly. 
Chandra et al. (2003) found that in 2000, only 70.0% of physicians were 
ordering MSS within the correct range of 15 to 20 weeks. She also found that 
family physicians ordered MSS at the incorrect gestational age more often than 
obstetricians. 
Physicians did not seem to differ with regards to how MSS affected their 
medicolegal risk. Approximately the same percentage of physicians thought that 
MSS increases their medicolegal risk as those which reported that MSS decreases 
their medicolegal risk; 48.4% of physicians reported that MSS had no effect on 
their medicolegal risk. 
In the survey completed by Chandra et al. in 2000, 20.0% of respondents 
thought that MSS influenced their medicolegal risk and 41.0% thought that MSS 
did not alter their medicolegal risk. The physicians who felt that MSS affected 
their medicolegal risk in Chandra's study cannot be compared to our study, as the 
question posed by Chandra et al. did not specify a definition for the term 
" influenced". It could be taken to mean either increase or decrease in medicolegal 
risk. 
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When physicians in our survey were asked about the timing of prenatal 
screening, 70.8% of family physicians and 78 .0% of obstetricians reported 
preferring a first trimester screening test. Prenatal screening is currently being 
offered throughout Canada, with many larger centers using a combination of first 
and second trimester screening to increase sensitivity and specificity screening 
rates. There is presently nobody trained in Newfoundland and Labrador to 
measure the ultrasound markers utilized in the current first trimester prenatal 
screening test. 
These findings suggest that for the time being MSS is the only option for 
Newfoundland and Labrador physicians. There is still room for improvement with 
respect to physician MSS knowledge. More continuing medical education is 
needed on the topic of prenatal screening, as previous MSS education and 
promotion have been only moderately successful. 
5. 7 Patient familiarity with MSS 
The most common source of MSS information among women surveyed 
was their family physician; 45 .3% reported that they had discussed MSS with 
their family physician. This compares with 24.1% and 11.8% ofwomen who 
discussed MSS with their obstetricians or family and friends respectively. There 
were no differences reported in sources ofMSS information among women from 
different sized communities. Of the women in our study who discussed MSS with 
their physician, 53.8% chose not to undergo the screening test. 
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Exactly what women in Newfoundland and Labrador know about MSS is 
not known. Also unknown is why so many women decline MSS when it is offered 
by their physician. This is a potential area for further research. Education of 
women about MSS is also warranted. 
5.8 False positive screening results 
There were no true positive results reported by the Provincial MSS 
Program, ie. there were no open NTDs, DS, or Trisomy 18 babies born to women 
screening positive. The lack of open NTD true positives maybe partly explained 
by the recent fortification of food with folic acid throughout Canada. 
The Provincial Maternal Serum Screening Program reported false positive 
rates of2.9% (n = 28), 9.8% (n = 95) and 0.4% (n = 4) for open NTDs, Down's 
Syndrome and Trisomy 18 respectively among the women screened in 2003. This 
gave an overall false positive rate of 13.1% in 2003. This false positive rate is 
higher than that reported by the Ontario MSS Program which reported an overall 
false positive rate of9.4% between October 1993 and September 2000. Ontario's 
rate was comprised of2.0%, 7.2% and 0.2% false positive rates for NTDs, 
Down's Syndrome and Trisomy 18 respectively (Summers, 2003). 
The high number of false positives associated with MSS was reported by 
physicians as a negative aspect associated with MSS. Reasons that were reported 
by physicians for not offering MSS were the large number of false positives 
associated with the test, the complexity of explaining the test and outcome to 
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patients and the undue anxiety that the test created in patients. 
Similar rationales were reported in other studies which examined 
physician opinion ofMSS. Green (1994) and Chodirker (1989) both found that 
patient anxiety was a common concern expressed by physicians. Physicians have 
often reasoned that MSS causes undue anxiety in their patients and, therefore, 
offering MSS does more harm than good. With this in mind Goel et al. (1998) 
completed a study on MSS and patient anxiety by following 2020 women who 
underwent MSS in Ontario. This study determined that MSS was not causing 
serious psychological harm to women and that women were not as concerned as 
practitioners thought. 
In my study, of the women who underwent MSS screening and who 
received a false positive screening result, only 73% reported that they would not 
undergo MSS screening in their next pregnancy. This finding was also reported in 
a study published in 2000 by Rausch et al. In an age-matched comparison, 108 
women who had a false positive in a previous pregnancy were significantly less 
likely than 108 women who were screen-negative to participate in maternal serum 
screening in their next pregnancy. The investigators proposed that reducing the 
false positive rate in prenatal serum screening would alleviate maternal anxiety 
and would probably lead to more stable participation among women undergoing 
MSS in subsequent pregnancies (Rausch et al. , 2000). 
The Provincial MSS Program reported that women over the age of35 
accounted for 13 .9 % of the samples analyzed and had a false positive rate of 
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32.6%. Women under the age of 35 accounted for 86.1% of the samples and had a 
false positive rate of 5.9%. Older women are at an increased risk for carrying an 
affected fetus; this group would therefore be expected to have increased false 
positive and true positive rates associated with their pregnancy. The increased 
false positive rate associated with MSS in Newfoundland and Labrador may be 
explained by the large number of women over the age of 3 5 undergoing the 
screening test. 
Normally, samples which are analyzed outside the 15 to 20 gestational 
week timeframe would give inaccurate risk assessments and inappropriate false 
positive rates. However, these samples are not likely to blame for the elevated 
false positive rate associated with the Provincial MSS false positive screening 
rate, as the Provincial MSS Program omitted these samples before calculating the 
overall rate. The high false positive rate in women over the age of35 years of age 
is likely contributing to the overall false positive rate. 
This is a potential problem associated with selective based screening. MSS 
uses population-based risk ratios and therefore offering the screening test to 
certain groups of women skews the overall false positive rate. Physicians 
complain that there is an extraordinarily high false positive rate associated with 
MSS but it may be their MSS practice which contributes to this problem . 
. Physicians should understand that MSS benefits younger women, as well as, if not 
better than older women. Younger women experience the three prenatal diseases 
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screened by MSS, but do not have the high false positive rates associated with the 
screening test as compared to women in older age groups. 
Also, the high false positive screening rate described in the study may be 
explained by the biochemical marker thresholds or cutoffs set by the screening 
program. In addition, there is the potential to lower the false positive rate by 
expanding the maternal serum screening program to include a fourth biochemical 
marker, inhibin A. 
5. 9 Limitations of study 
There are several limitations to my study. Data from the physician 
component of our study came from self-reported questionnaires. This type of 
information relies on the individual to report his or her information and may select 
individuals who are more interested in the area being studied. It may also select 
individuals who are more likely to practice evidence based medicine and therefore 
would be more familiar with MSS. 
Another negative aspect of self-reporting which may compromise the 
validity of our findings is that respondents may be more likely to report socially 
acceptable responses. Many consider MSS a controversial screening tool, as it 
involves identifying fetuses with genetic abnormalities with the possibility of 
pregnancy termination. Physicians may report offering MSS more because of its 
perceived importance to public health or anecdotal evidence suggests that they 
may offer MSS less because of religious reasons. Physicians may, therefore, 
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withhold their true MSS practices and beliefs and report more socially desirable 
responses. 
In the patient section of our study, there would also be recall bias 
associated with the self-reported nature ofthe questionnaires. Women were 
surveyed up to 20 weeks after the screening window. Some women may have 
forgotten which tests were offered and ordered by their physician. Another 
limitation of the patient survey was that it did not encompass the entire province. 
Only women who gave birth at the Women's Health Centre in St. John's were 
surveyed. The Women's Health Centre is located in a major tertiary care hospital 
and would have serviced more high risk pregnancies. There might have been a 
selection bias associated with this aspect of my study. This somewhat different 
patient population was discovered when the Provincial MSS uptake rate was 
compared to the uptake rate reported by patient component ofthe study. The 
women in our study reported a MSS uptake rate of 27%, whereas the overall 
uptake rate for the province was 22%. 
Lastly, a limitation associated with the laboratory data was that the 
information was only available in aggregate form (and the analysis was therefore 
somewhat limited). 
5.10 Strengths of study 
The main positive aspect associated with our study was that there were 
three sources of information regarding MSS in Newfoundland and Labrador. 
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Information came from each group involved in prenatal screening in the province: 
physicians, patients and the Provincial Medical Genetics Clinic. A more complete 
picture of MSS was available because of this triangulation of information. 
Another strength associated with this study was the high response rates 
obtained from the physician and patient components of the study. The samples 
also seemed to be representative of each population. 
Lastly, the impact of the new MSS Program in Newfoundland and 
Labrador was analyzed. This program was established after the survey of 
physicians done by Chandra et al. (2003) and therefore the impact of the 
Provincial MSS Program was examined in this study. 
5.11 Recommendations 
Since its introduction, the Provincial MSS Program has had modest 
success in physician awareness and uptake. This study found that there are still 
women not being offered MSS by their physicians. Some physicians still report 
being unaware ofMSS in Newfoundland and Labrador. This was also reported by 
physicians in the 2000 survey of physicians done by Chandra et al. (2003). Since 
Chandra's study however, there has been a team which crossed the province 
conducting seminars to inform prenatal care providers of the government-funded 
MSS program. 
This continued lack of awareness, especially in rural areas, could be 
explained by the high turnover rate of physicians in Newfoundland and Labrador. 
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New family physicians are continuously recruited to these areas, some of whom 
may not be familiar with the programs available in Newfoundland and Labrador. 
Physicians in our study reported a definite lack of knowledge surrounding 
the details of the screening test. Continuing Medical Education sessions on MSS 
would benefit all physicians and may serve to increase the MSS uptake rate in the 
province. Professional organizations that represent physicians could also take a 
more active role in disseminating information on new practice guidelines. Special 
efforts could be made to reach older male physicians as our study found that this 
physician group was less likely to discuss and offer MSS. 
Educating women of childbearing age about MSS may be another option 
to increase MSS screening. Workshops, public service announcements and 
distributing MSS brochures at baby clinics, community centers and family 
practices may serve to educate and inform pregnant women. Although the risk for 
Down's syndrome increases with maternal age, an estimated 75% of affected 
fetuses are born to mothers younger than 3 5 years of age because of the number of 
women giving birth at this time (Loncar et al., 1995). It is, therefore, important to 
inform women of these risks and to provide all pregnant women the option of 
noninvasive screening. 
It is recommended that a further review of the Provincial MSS screening 
rates is warranted. The high number of false positives associated with the test was 
reported by physicians as a reason for not offering the test to all their patients. 
Upon analysis, it was discovered that the false positive rate for the province was 
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much higher than the recorded literature value. An investigation into this rate may 
be able to address one of the complaints physicians have with the MSS Program. 
A cost benefit analysis of the program is also warranted. In 2003, there 
were a total of 1049 samples analyzed by the Provincial MSS Program, resulting 
in 127 false positives. There were 0 true positives. The Provincial MSS Program 
utilizes many different groups and resources throughout the health care system. In 
2003 it did not discover one affected pregnancy. As developments and demands 
increase in the health care delivery system, new programs should be analyzed 
thoroughly to ensure their cost effectiveness. 
More study on patient knowledge and attitude of MSS would also be 
useful. If repeated, the patient survey could be expanded in certain sections. 
Asking patients more specifically about their conversations about MSS with their 
physicians would give a more accurate account of how MSS information is 
presented to women in Newfoundland and Labrador. These additional results 
could be used to examine how information influences their decision to undergo 
screening. Other patient studies of maternal serum screening have indicated that 
the nature of the information given to women, and how it was presented, 
influenced whether screening was done (Marteau et al., 1992; Gekas et al., 1999). 
Also asking women more personal questions about their socioeconomic 
background may determine specific groups who are not being offered the 
screening test. 
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As this is the first prenatal genetic screening program in place in the 
province, further analysis of overall MSS knowledge and opinion is warranted. As 
genetic tests for diseases proliferate, the interest and attitudes of primary care 
physicians, specialists and the general public will be of paramount importance in 
the diffusion of new genetic tests (Holtzman, 1992). 
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Chapter 6 - Conclusion 
Newfoundland and Labrador introduced a formal Provincial MSS Program 
in 2001. MSS is a blood test done in the second trimester of a woman's pregnancy 
which gives a risk assessment for carrying a fetus with Down's syndrome, open 
NTDs and Trisomy 18. A positive screening result identifies women who should 
have invasive testing such as amniocentesis, to definitively determine the status of 
the fetus. The goal of the Provincial MSS Program is to offer population based 
screening, as MSS is used widely across Canada and is considered the "standard 
of care". However, in Newfoundland and Labrador few women are undergoing 
the screening test. To examine this low MSS uptake rate we used a physician 
survey, patient survey and aggregate laboratory data to examine the knowledge of 
and attitudes towards MSS in Newfoundland and Labrador. 
In October and November of2003 we surveyed all physicians involved in 
antenatal care in the previous twelve months. In November and December of 
2003 we completed a survey of300 women who had given birth at the Women's 
Health Centre in St. John's, Newfoundland. The patient surveys were completed 
by patients in hospital within forty-eight hours of giving birth. In March of 2004 
we collected the Provincial MSS Program's aggregate laboratory data from 2003. 
These data provided the uptake rate, screening rates and the age breakdown of 
women who ordered MSS in that calendar year. 
With the introduction of the Provincial MSS Program a team crossed the 
Province on a MSS promotional and educational tour in the summer of 2002. 
These sessions seemed to influence physician MSS practice. The main finding of 
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the physician survey was that a greater number of physicians were offering MSS 
and more of these physicians were offering MSS to all pregnant patients. Chandra 
et al. (2003) reported that in 2000, 16.0% of physicians were not offering MSS 
and only 29.0% were offering it to all women. In our study the percentage of 
physicians that were not offering MSS had dropped to 11 .2% and the number of 
physicians that were offering MSS to all women had increased to 56.1 %. 
Obstetricians were found more likely to offer MSS to all their patients, 
whereas, family physicians were more likely to offer the screening test only to 
women deemed to be at high risk. Obstetricians and family physicians did not 
differ significantly in their knowledge of the specific screening rates and false 
positive rates surrounding MSS. However, obstetricians did order MSS more 
often within the correct gestational timeframe and also reported positive screening 
results back more quickly to their patients. 
A difference was also found between male and female physicians. Female 
physicians were more likely to offer MSS to all their patients and also ordered the 
test more often within the correct timeframe. Females were also more likely to 
report positive results back to their patients more quickly than their male 
colleagues. Female physicians were younger and had more likely to have 
graduated from a medical school in Canada. 
The patient component of this study found that the older groups of women 
surveyed were more likely to be familiar with, and discuss MSS with their 
physician. Older patients in our study were also significantly more likely to 
undergo MSS and amniocentesis . 
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The Provincial MSS Program reported an overall MSS uptake rate of 22%. 
This uptake rate was found to be much lower than other MSS programs, inside 
and outside of Canada. 
The Provincial MSS Program had an overall false positive rate that was 
much higher than that found in the literature and among other Provincial MSS 
programs. 
Overall, a fairly extensive analysis was completed ofthe Newfoundland 
and Labrador MSS Program. My study found that MSS is still being used as a 
selective screening tool. This is a cause for concern as MSS is meant to be a 
population based screening tool. MSS uses population-based risk ratios; it is 
inappropriate to recommend MSS solely to women in high risk groups as it 
cannot give accurate risk estimates. This may explain the high false positive rate 
found in the province. 
This raises an interesting ethical question for physicians. One of the 
concerns physicians had with MSS was the anxiety caused by the high false 
positive rate associated with the screening test. Physicians themselves are driving 
the false positive rate associated with MSS upwards by offering the test more 
often to older women who are more likely to screen positive. 
Given these findings regarding physician MSS practices it is suggested 
that continuing medical education be implemented in this area. This study showed 
that educational sessions influence physician MSS practice and may improve 
prenatal screening in the province. Future educational sessions should particularly 
concentrate on older physicians, especially those who are male and practicing in 
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rural areas. Professional organizations that represent physicians could also take a 
more active role in disseminating information on new guidelines, especially to 
physicians new to the province. 
A more extensive patient follow up survey is recommended. This more 
focused study may be useful in determining why so few women are choosing to 
undergo MSS screening when it is discussed with their physician. Examining the 
interaction between patient and physician may give more detailed information 
into this question. Another recommendation is education and promotion of MSS 
to women of childbearing age and physicians practicing family medicine in the 
province. 
It is also recommended that further review is warranted with regard to the 
high false positive rate associated with the Provincial MSS Program. 
Only 22 % of pregnant women in Newfoundland and Labrador underwent 
MSS screening. Only 63.5% of physicians offered MSS to all their patients. This 
finding suggests selective screening still exists since the 2000 Chandra et al. 
survey and ensuing educational and promotional sessions throughout the 
province. There continues to be a need to educate both patients and physicians on 
the importance of screening all pregnant women. 
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Appendix A 
September 1, 2003 
Dear Physician, 
As you might be aware, Maternal Serum Screening (MSS) is currently offered in Newfoundland and 
Labrador. I am a M.Sc. student in the faculty of Medicine and am interested in physician practice~ 
knowledge and opinion of this relatively new screening program. Attached you will find a 
questionnaire asking questions regarding these points. 
There are no possible risks with this study and the time required is the few minutes that it takes to fill 
out and return the questionnaire in the enclosed envelope. You may contact the investigator at the 
below contact information at any time to inquire further about the study. 
The results of this research study may be published but your name or identity will not be revealed. In 
order to maintain confidentiality of your questionnaire, your name and address have not been added 
to either the questionnaire or return envelope. As with any study of this size, we will be required to 
contact physicians who do not respond. Due to this fact a return postcard with your name and 
address will also be found in this package. Mail this postcard separately the same time the 
questionnaire is returned. This will ensure anonymity of responses while providing us with a list of 
physicians who have completed and returned the questionnaire. 
Thank you for your attention in this matter, your response to the survey will assist in the 
identification of issues and concerns related to the Provincial Maternal Serum Program. If you would 
like information regarding this program please contact the MSS Coordinator at the Provincial 
Medical Genetics Program at (709) 777-4363. If you would like to receive the results ofthis study 
please contact me at the below address. 
Yours truly, 
Mr. John Cavanagh 
Graduate Student 
Division of Community Health 
Faculty of Medicine 
Memorial University of Newfoundland 
St. John's NL AlB 3V6 
phone: (709) 777-8384 
fax: (709) 777-73 82 
email: jpcnfld@hotmail.com 
Dr. Maria Mathews, PhD 
Assistant Professor Health Policy/Health Care Deli very 
Division of Community Health 
Faculty of Medicine 
Memorial University ofNewfoundland 
St. John's NL AlB 3V6 
phone: (709) 777-7845 
fax: (709) 777-7382 
email: mmathews@mun.ca 
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SECTION I- Physician Personal and Practice Characteristics 
Please answer each of the following questions by placing a tick ( 0 in the appropriate box. 
1 . What is your specialty? 0 Family Medicine 0 Obstetrician 
0 other (specify): ____ _ 
2. What is your gender? 0 female 0 male 
3. What is your age? 0 <30 0 30-39 0 40-49 0 50-59 0 60+ 
4. Where did you attend medical school? 0 Canada 
0 United States 
0 other (specify): ____ _ 
5. How long have you practiced in Canada?_ year(s) 
6. What are your practice certifications? 0 CCFP 
O FRCP 
0 other (please specify): ______ _ 
7. How large is the community in which you practice? 0 urban (>20 000) 
0 semi urban (1 0 000 - 19 999) 
0 town (5000- 9 999) 
0 small town (1 000- 4999) 
0 rural ( <999) 
8. Do you provide antenatal care as part of your practice? 0 yes 
0 no - if NO, PLEASE STOP HERE 
and go to the end of the questionnaire, 
thanks for your time. 
9. Approximately how many years have you provided antenatal care?_ year(s) 
10. Up to what gestational week do you provide antenatal care? 0 0-14 weeks 
0 20 weeks 
0 28 weeks 
0 0- term 
11. Approximately how many pregnant women have you cared for in the past year? _ 
12. Do you perform deliveries as part of your practice? 0 Yes, about_ deliveries per year 
0 No 
The nextfew questions relate to your knowledge and opinion of maternal serum screening. 
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SECTION II- Knowledge and Opinions of Maternal Serum Screening 
13. Do you offer pregnant women in your practice the opportunity to have Maternal Serum 
Screening (MSS)? (Please check one) 0 yes- if Yes, skip to question 15. 
0 no- if No, go to question 14. 
Answer this question if answered NO to question 13. 
14. What are the reasons that you do not offer MSS? (Check all that apply) 
0 Too many normal pregnancies have positive MSS results 
0 MSS is incompatible with my religious beliefs 
0 I was unaware that MSS was routinely available in this province 
0 It is too difficult to explain the test and its possible outcomes 
0 Too many abnormal babies are missed, too many false positives 
0 MSS is too costly 
0 MSS is too time consuming to explain 
0 It is too difficult to coordinate testing and follow up services 
0 It creates undo anxiety for my prenatal patients. 
0 Other (please specify): _________________ _ 
Answer these questions if answered YES to question 13. 
15. To which pregnant women would you routinely offer MSS? (Check all that apply): 
0 All pregnant women 
0 Women age 35 or older at their due date 
0 Women under age 3 5 
0 Women with a family history of Down syndrome or neural tube defect 
0 Any women who ask to be tested 
0 Other subgroup ofwomen: _______ _ 
16. How much time do you typically spend discussing MSS with a patient? __ minute(s) 
17. What percentage of pregnant women <35 of age offered MSS chose to have it? % 
18. At what gestational age do you order MSS? __ week(s) 
19. When do you communicate positive MSS results to patients? 0 within 48 hours 
0 within 1 week 
0 within 2 weeks 
0 at next clinical 
appointment 
20. When do you communicate negative MSS results to patients? 0 within 48 hours 
0 within 1 week 
0 within 2 weeks 
0 at next clinical 
appointment 
Please go to question #21. 
The next few questions are some background questions regarding MSS. 
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21. How far away by automobile are follow up MSS services amniocentesis hours 
level II ultrasound hours 
----
genetic counselling hours 
22. What do you think is the false positive rate associated with MSS? % 
23. What percentage of affected fetuses do you think MSS will correctly identify? 
Down syndrome __ % 
Neural Tube Defects % 
Trisomy 18 __ % 
24. Do you believe MSS misleads patients to believe that physicians can guarantee a healthy baby? 
0 yes 
0 no 
25. Where have you read or heard information pertaining to MSS? (Check all that apply) 
0 Medical journals 0 Newspapers 0 Colleagues 
0 NLMA newsletter 0 Hospital rounds 0 Patients 
0 Internet 0 CME sessions 
0 Provincial Medical Genetics Clinic information pamphlets 
26. Have you changed how you deal with MSS in the last 18 months? 0 yes, I offer MSS more 
0 yes, I offer MSS less 
0 no change 
0 not sure 
27. Would you prefer MSS be offered in the first trimester of pregnancy? 0 yes 0 no 
28. Do you feel that the MSS test is altering your medicolegal risk? 0 yes, 
unchanged 
0 no, 
more risk less risk 
29. Are you aware of a Provincial Maternal Serum Screening Program? 0 yes 0 no 
30. What is your opinion of the MSS program? 
31 . Any comments: 
Thank you. Please mail questionnaire in return envelope provided. 
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Appendix B 
Newfoundland and Labrador Physician Practice, Knowledge and Opinion of 
Maternal Serum Screening 
In-Hospital Patient Questionnaire 
Date of Questionnaire Completion: 
Month Day Year 
The Faculty of Medicine along with the Provincial Medical Genetics Clinic is 
studying prenatal screening in Newfoundland and Labrador. We are asking patients 
who have recently given birth about the prenatal screening experiences during their 
pregnancy. We are questioning patients at the Health Sciences Centre to better 
understand the use of health care services. The questionnaire will take 2 to 5 minutes 
to complete. 
This study has been approved by the Human Investigations Committee at Memorial 
University. You should also understand the following points: 
You may choose not to answer a question and your participation is completely 
voluntary. 
If you have any questions or comments please do not hesitate in contacting the 
primary investigator graduate student John Cavanagh ofthe department of Medicine 
at 777-8384 or Dr. Maria Mathews at 777-7845. 
Please do not provide your name on the questionnaire, as your answers will be kept 
confidential and we will not identify you in any report or presentation. We will not 
share your answers with anyone including your doctor. 
Whether or not you decide to participate, your care will not be affected in any way. 
When the questionnaire is completed please seal in the envelope provided give to one 
of the medical services aid upon their return. 
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Human Investigation Committee 
Research and Graduate Studies 
Faculty of Medicine 
The Health Sciences Centre 
August 1, 2003 
Reference #03.62 
Mr. John Cavanaugh 
c/o Dr. M. Mathews 
Community Health 
Faculty of Medicine 
Dear Mr. Cavanaugh: 
Appendix C 
KEYED 
J.:..viJ 0 1 Z003 
This will acknowledge receipt of your amendment form dated July 29, 2003, wherein you 
---------provide an amendment dated July 29, 2003 to your research study entitled "Newfoundland 
and Labrador physician practice, knowledge and opinion of maternal serum screening" 
The Chairs' of the Human Investigation Committee reviewed your correspondence and granted 
approval of the amendment dated July 29, 2003 as submitted. This will be formally reported to 
the full Human Investigation Committee at the meeting scheduled for August 7, 2003. 
Please be advised that the Human Investigation Committee currently operates according to the 
Good Clinical Practice Guidelines, the Tri-Council Policy Statement and applicable laws and 
regulations. 
Sincerely, 
Sharon K. Buehler, PhD 
Co-Chair 
Human Investigation Committee 
SKB;RSN\jd 
RichardS. Neuman, PhD 
Co-Chair 
Human Investigation Committee 
C Dr. C. Loomis, Vice-President (Research), MUN 
Mr. Wayne Miller, Director of Planning & Research, HCCSJ 
8 4 
St. John's, NL, Canada AlB 3V6 • Tel.: 1709) 777-6974 • Fax: (709) 777-7501 • email: hic@mun.ca • www.med.mun.c:alhic 
Mr. J. Cavanagh 
Grad Student 
Community Medicine 
General site 
Dear Mr. Cavanagh: 
HealthCare 
-~ .• • 'J II<".(_ 1 .~ of ~~ . ! l:h ! • -: 
Appendix D 
September 17, 2003 
Your research proposal "HIC # 03.062- Newfoundland and Labrador Physician practice 
knowledge and opinion of maternal serum screening" was reviewed by the Research 
Proposals Approvals Committee (RPAC) ofthe Health Care Corporation of St. John's at 
its meeting on September 16, 2003 and we are pleased to inform you that the proposal 
has been approved. 
Ongoing approval ofthis project is dependent upon the continued support of the Director 
and Clinical Chiefs of the Children's and Women's Health Program. 
This approval is based on the understanding that it has the necessary funding and that it is 
being conducted as outlined in the approved research proposal. Additionally, the 
Committee requires a progress report to be submitted annually. 
If you have any questions or comments, please contact Lynn Purchase, Manager of the 
Patient Research Centre at 777-7283. 
Sincerely, 
Mr. Wayne Mi r 
Director, Planning and Research 
Chair, RPAC 
cc: Ms. Pamela Elliott, Vice President Quality and Planning 
Ms. Lynn Purchase, Manager, Patient Research Centre 
St. Clare's Mercy Hospital 
154 LeMarchantRoad, St. John's, NL, Canada AlC 5B8 Tel. (709) 777-5000 Fax (709) 777-5210 
Website: www.hccsj .nf.ca 
SIrES: H~a lth Sc i ence~ Centre (Cteneral Hn~p i tn.! 'J a ne\,ay Cluldren\ Health and Rehab il llntton Cemre'Women·s ll ca lth Centr~l 
lJr. LCI'llard \ .. lilkr Centre • St. Cl.ue·~ i\h:rr·, l lt•~pit,d • D.-. \\allel Tt.nlpkman I kalth C.:ntre • \ ' aterforol Hospital 
Patient Questionnaire 
The first questions are to help describe your background. 
1. In what year were you born? _____ _ 
2. Approximately how large is the community that you live in? 
D urban (greater than 20 000 people) 
D semi urban (10 000- 19 999 people) 
D town (5000- 9 999 people) 
D small town (1000- 4999 people) 
0 rural ( less than 999 people) 
3. Have you heard of Maternal Serum Screening (MSS)? 0 yes 
D no 
The next few questions are to give us an idea of your experiences with prenatal 
genetic screening, specifically MSS. MSS stands for Maternal Serum Screening 
and is a blood test taken between 15 and 20 weeks of pregnancy. This screening 
test determines a woman's risk of carrying a fetus with Down's syndrome, · 
Trisomy 18 or open Neural Tube Defect. 
4. What prenatal tests did you undergo? (Check all that apply) 
D ultrasound 
D amniocentesis 
0 MSS 
0 other (please specify): __________ _ 
5. Where did you first hear about MSS? 
D family physician 
Dobstetrician 
D never heard of MSS until now 
(Check all that apply) 
D media (newspaper, radio, internet, etc.) 
D public health nurse 
D friends or family 
6. Did you see a physician between the 15 and 20th week (2"ct trimester) of your 
pregnancy? 
D no 
D yes, if Yes which type of physician (check all that apply) 
D family physician 
0 obstetrician 
D can't remember 
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7. Did your physician discuss MSS with you? 
0 yes, if Yes for approximately how many minutes? __ minute(s) 
0 no 
0 can'tremember 
8. Did you choose to undergo MSS testing? 
0 yes, if Yes please proceed to next question. 
0 no, if No this is the end of the questionnaire. Please seal questionnaire 
in the envelope provided and give to one of the medical service aids 
upon their return. 
0 don't know, if No this is the end of the questionnaire. Please seal 
questionnaire in the envelope provided and give to one of the medical 
service aids upon their return. 
9. Do you think you would choose to undergo MSS testing in your next pregnancy? 
0 yes 
0 no 
10. What was the MSS result? 
0 screen positive (test positive), if screen positive please proceed to next 
question. 
0 screen negative (test negative), if screen negative this is the end of the 
questionnaire. Please seal questionnaire in the envelope provided and 
give to one of the medical service aids upon their return. 
0 don't know, if don't know this is the end of the questionnaire. Please 
seal questionnaire in the envelope provided and give to one of the 
medical service aids upon their return. 
11. Did you receive counselling for your screen positive (test positive) result? 
0 yes, if Yes please proceed to next question 
0 no, if No this is the end of the questionnaire. Please seal questionnaire 
in the envelope provided and give to one of the medical services aid 
upon their return. 
12. Who counselled you about your positive result? 
0 family physician 
0 obstetrician 
0 genetic counselor 
0 psychologist 
0 other (please specify): __________ _ 
This is the end of the questionnaire. Please seal questionnaire in the envelope 
provided and give to one of the medical service aids upon their return. 
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